var title_f15_34_15904="Saline injection prior to EMR";
var content_f15_34_15904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cartoon depicting the use of saline injection prior to endoscopic mucosal resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Simulated dysplastic lesion (red mark depicts dysplasia).",
"    <br>",
"     (B) Isolation of the lesion with submucosal fluid injection.",
"     <br>",
"      (C, D) Snare excision of isolated dysplastic lesion.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Christopher Gostout, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15904=[""].join("\n");
var outline_f15_34_15904=null;
var title_f15_34_15905="Upper cut test for SLAP lesion";
var content_f15_34_15905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82891/Upper_cut_test_video.mp4?title=Upper+cut+test+for+SLAP+lesion\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Upper cut test for SLAP lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 316px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE8AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxWnDpTetKOte0eYOU04HrXqfgL4NyeLvCWn66PFFpYi8Dn7O9tvMe12XrvGfu56d66Rv2cLtY/MPjC1EePvGw4/PzKw+s0zb2M2eFL0p3pXefFb4aS/D3QLfVDr9tqqy3HkGGO38sj92z7s7z/dxjHeoPiB8O7nwXoegalLqsd+urHHlLbeWYj5Xmddxz6dBVRrwdvMl0ZI4wGlFMQhuhBxwfanr0rczHY9acDTVYMDgg49DmloJHdadXTfDTwZP488RXWlW+oR6eYLT7UZHgMu75wu3G4Y65zWX4n0eTw74m1XRZblbprGfyvPWPYH+VWztycfe9ahVIuXJ1NHB8vMUB9KevSu3+F/w2uvH9vqU8GsRacllMkO1rUzF9ybic7lx6YrhYSxBDY3I7o2OhKsV/pmiNSMpOK3QODSuyUU6mkgEBiAT0z3pw44rS5IoFOz0yKaTgZyMetDMAoOcg9xQ3ZXGldg8mwZKkr3I6j8KpXOtw26EOcliFz/Wq97d+WSCelczeOsvnyxbiAR15wK8qrXbd7nfTpK1ja1fVHuYnhtycswXINXdEF21zi4YSXDr93sg+vauQsXaOQsp+bsT2rpPDV3GrXAdzhVy7ZyW7nP4VyVZzaN4QijQvdWWCSMBFESHJI9u3ufeuo0m58/TReXTYLERxxjhVU9a8t1HUkvJZGigYYbKMzZJ/DoB7V6z8JvBHibxqjPYRW8ekwPte9uyRG0g6hFXlyO/Qds9q53Tk0aKUUU7qSaS7WKzAHmDfvblUyPmOPbHSmSrFEY41l8wMPlZjgtzXrlz8HTZ3BjPjjS11Bh/x7z2ipknt/rd1ef65ot14X8QXGk6hHbvNaFWlltmLI4ZN4I3DI+h79DXVh6s6DuY1YRq6GGUKsQe1KKtXTLKivEH2P2YYOaqjua9+hVVWHMeXUhySsLThTRDdSWdzeW9s0tnZyRx3U5bakTSMFVf9piTnaOg5OOMuxjrWkZKTaXQzaa3DtT1q54e0qTXvEmm6PFdw2bXruv2iZN6oFjZ+mRknbjrXpkPwPv5SVh8WabIQMkLZE/ykrKpiadJ8sjSNGU1dHlOKUYHevVn+CF7HJsk8W6ajf3WsiD+XmV5dc27WV9qFnLLFM1ndS2zTRjCybGK7gMnGcetOniKdR2iTOjKCuxg6U4dRSLzyvI7EU7GFLNgAdycVuZDgMUoo4wD2PQ0hW5Nu11DatJYxXKWk10ThElcEhF/vNgZIH3QRnk4qZSUd2Ci5bEgFOUdcUYPHv3pwHGaoQoHFLQKUDNACinUgFOHagBQKeopMAdacPagBR1pwHNIP0pw60AFOFAHFKtAxQKcKQdacBxQAv9acOtNUDFOxQDFp31P6UgFO49KQBilAIpR24NLSATFGKWikMTbmkK8VJijaaQIqSJxRVlk4PFFTYo8VpR0pBSisiyGe3haKQmNckHP5V9QfExQf2WdLU9Psemjr/tRV8ySAtG4HJKnA/CvefHfjnwzqP7PmnaFY61aT6wltYRtaIx8wMjR7xjHbac/SuTER96NjoovR6ngV5BGljcsqKD5T4wPY19S/GSTw7aeAfBl74ns7jUhAIza6bE/lrdSGDkSP1EajJOOvA56V8vXoLWVyqjLGNgAPoa9m+N3i7QPEXg7wXZ6Jq1re3VmQbiKJstGPs+3J9OeKK8LzikOjL3Wzb1vSvCXjb4H6h4q0Xw5aaDqmlrJgWyKpR4iNyFlAEiMvqO/qKx/hl4H09/h3qnjfWNDn8R3EbSLp2jorMshRtu4qudxLZ6ggKOhNV/BfizQNO/Z+8VaBfarbQ6zcvd+TaOx8yTeF24HvVj4T+PdFtPBOpeCfFl9d6Ta3BkNpqcBZfK8w5KlhkoytyCRgg4Pvi1LllFbJmicW03vY2fC3hWP4i6dq9hrvgKPwnrFtEJbDU7OxktY2JyNjBgN+CBkHIIOeDXhcJYxjzV2yDKuo7MDgj8wa9CutG02zdm1D4xia0XJj+wPcT3MnoAgkIDH8q86tQwgQMCGxznr+PvXRhr3a6GNfZHsf7Lf/ACUfVj/1CD/6OSuR+LqMnxV8VK67T9rVgD6GJCD+NZ3gLxTc+C/FlprdpD9oWNWhuLfdt86FsblB7MCARnjIx3r2bxLffCH4kXEGq6lrsmk6msYSU+abSZlHRZFZSrYycEZ9jilNulW52tBwSnT5blj9lJGGjeJXKnY19GobsSIlyP1H51538AtA0rxD8QLyz13T7bULaO2upViuEDqG+0ABsHvgnn3ruNW+JnhDwT4Obw98Mib27ZXCXCBmihdvvTSSt99++BnJwOBXM/swII/iNOgJO3SpBk9T+9j5NYtScZzta/8AmaXScYlmx1nwBo/j6/8ADreArJ9Nl1NrCW+uWWZ0kL7QVjKnbEGIACkEDnFZXxS8D6f4T+JGjadZRl9E1SaCRLaUlhEPPRJIsnkodwIB6ZI6Yrbn0LwD/wALL1PV9T8cwQw2uqyXV1pdzD5UouEk3bN5PzR7xngEkDGaw/iF4yt/G/xQ0S905ZBpdndW1ravIpUz5uEZ5Np5AJAAzzgZ70Q3vC+2o5f3u51XxWg8EeAvF+mrZeA7DUb6a0MhiZxDbKgcjOzaQ0hORkjgAVkfF/wt4duPhlY/EDwdZjS4JRE91axDYjJIduSg4Do5AyvUZ68V1vx40bw5q/jHSl1XxbH4e1MWRCC5tvMhkh8w8hsgBwc8E8+lcR8Y/Gfh2L4cad4C8F3R1Cyh8pbq7HKbIzu27iBudmAJ28Dn6Vle0U43uVa7aexZ8P8AgS08KfCjTvFM3hJvGHijVfLeK2khe4itUkBZSY1B4CgEnGSTjIFM1jwRb+NvhXrWuz+C/wDhEfFOkb5NkNq9rFeRIoc/u2AyCuRnkhh17VJ4V8f+H/FfwrtPB/iXxFc+GNYsUSO11GN2RJRHwjBlwPu/KyEj1B6Ecfq2iW8GlXwl+KL6zemIrb2OmtcT+eTwFkZnKqh757d6wb0ubRjrY6r4U+AtD8SfADV7qbTNMGrNLcompXES74EBHz7+o2rk/hXM+O/EXw7l8C22h+A/D0q38dxGBqFzZ+XLLEOXkEn3iXwBg44boOldZ4Z1/RtP+B/ibw3LexxarPcXCxWYDb3DsuMADoRUH/CI20hPyAEccVhUrqCXmddHCSqOXkeFz6RFY6fJMGdrk52R4wFHX8a+u9Qu5PBv7OGlS+H2a3IsLRPtEfWITFPMlHv87HPYnNeRXvglmdjCpYDru5rvvh/4stvD/hpvCXjezln0FY2hhu/JMyCFv+WM6AFhjOAwBGMZxjJKVRS3Yq2HlDWx4Nr+nwS+MZEhtVeLyw5Mq7mJx1JbJJPXJOe9dn4E0qG/8Y+FLTVYjfWt3eBLiK6cyqyrC+xcMT8oxwOnFdnN4W+FEF1JeweO7qG3lwWiW4WVwOyqzIXA9uTXF/234c8PfE6z1bw2lz/wj9jdW8uZA5luAEaOWTD/ADE4bcOmdvApqLi9zFvyJfjLp1hoPjfxLp2i2cNjaQ2cMqQ242KrGJssAPXAzXTfGXwvpGieGPBdx4f0yx0++vAVlmhiCGT9xn5iOvPPOeeaf8VZvhxrusS+K08YvP51qsVxpWmoJZbwJnCqesRIO0kjgelSfGPxd4e8S6V4Pi8O3sE5tnd5LeJi3kL5GACcdjgV34eTc4x8zlqxXK2dKdU0XT/2ddO1GDwrYz6fO0QOl3M29Gdptpd5CuWbI3biMk14xqVxb3urXN3ZaPY6LbyrGq2dmxaMFQQW6Dk59O1ek+Ftc8Kaz8IE8FeJNbXQr20c+XNIMbgsvmRyISNrDoCvXg9ODXnetWumWetSQaFrcmt2IgQtdmERJ5u5tyoABkABeeevWurCRUZtSTuYV23G62KUsUcybJo0kXrhlBFeg/s928Nv8T/3ESR7tMnzsXGfnirglFdh8JNe0vw34/jv9dvYrKzNhNEJZc7S5eMheB1wD+VdWLinSemphQb512KXxetraT4peKZbqGOTZJFlmXJCiCM109n4OtvDPw30nXT4VHibxBqZjeK2eB57axjdS4PlIDkBcAnGWY9QK5Lx9qdhrvj3xFf6ZcJd6fcyxqkyZ2uBCitjPuCK7Gw8WaR4j+HNl4X8Sa9c+G9Y07y1tdQQukNwEBVCWUgEFeGQkHPI7GuSrGSowa26nRFp1JXZDqHhmLWvhzqfiZPC58Ma/pMjNPbw28lvBfQqAxIjcDHyk4OMhlIyQasfDbw5pWpeA9a1uz0ax8S+KreWSOKwvnGyEA/u1Cngbk+fd1bOM+nDeINOtI9JvV/4T6LVb4piCx083M4nOfuyM7lVTGc5/OneHrSBphfW/ji18Oa0kzoBcwyRNHED8hSRTtlUjna+R1FZ2fs2r6X8ylbmTtqUvEM8t3qxjg8OWnhu+hQi7t7ffAJCWXB8pl/dttDgONwOepxXsuv6ro2n/A/wzcw+EtNudPu5LdYtLuJSYoWcM24vtJZgc/MRkkkmuW+MHifRfE+paCmi3C6jNp8coutRjj2I+5VAjU/xcjcQMgYHOTV3StZ8K+IfhRpnhfxDrq6DqmlmMq8q8boydrru+V1ZT0znk9CKco80ISkna4ou0pJPU88neKfUry5ttNtNKt53VksrRiY4sKAcZA5JGTxTqLyGzg1q7i0jVZdX0xViMV5JEIg74PmBQAPlBx6/U0Ae1enRacFbY4aqak7ijrSigDqegHJJ7VQu9ZsbZ4d9zGI5ELhk+bdjtVTqRhrJijBy0Ro4PQDrxQ8kcMYkmkSNP70jBf51x2o+J7i+jeDSEa3+XJlPLn2HYVzd482oTpJK8ksyjkzPk/l0rz62ZQhpDU7KeBlL4tDt7/xdp9vIywbrkKM70+6fp/jVZfGTO4Nrap5WOrscj/GuSt7d13RFV3jOHA+77EU5Y57diZYkRNpBfb0PYfWvOqZhWls7HbDB04rVXO/s/Els8MYmDee3VYh0Hrz2/WtNNSs3lWNJ1eRjhVUY7ZySeled2zs6ksAQyjAI+YH2NdDokcBCGZlHYoRyR7CsVjq6+0W8LSfQ7CN4mJ8uWNiCVxu5zj9adjnB9Kx3sPsk8UlymdhLIGkIRm/hww54H41cF3N9qVHezEKpukHIcfQ9D+lejh8yu+WocVbB2V4F7HWnKKjikjmUtC6yJnG5TkfnUwB7V7Caex57VtGIBTgPWgD1pwHFMQHrSilxxS4pAAFOAoApaBjcU4CjFOUUgFAwKUClAzSgYpDGMOKKfjiikwPC6XvSClFc5sLSgnrSUo60CH5qTKlB97d39MVDSg4HPSgZICT3NOzUYanAimhEi8dKUGm5pQaoCQHgZFOH8qjB5p4Oc8UxDwcnJJrtfhJ4vs/BHi+TVdStry4t5LJ7bbaqrOGLow4Zhx8p71xIqRaicFOPKyoScXdGhrt8mq+ItZ1KKOSKG9vprqNJMB1V3JAbGRmorG4FnqNhdsjyLbXUM7ImNzKkisQM8ZwKrDAFKDzTUFy8nQOZ83Mdx8XPGVl448U2epaZa3ltbwWX2ZhdoqszeYW4CseMV5n4mdlt49v8RxmtZeuax/FTD7HCP4i+f0rCrBU6LijWnLnqJsybBHuryKJOcDaBXqOkWK21mIh14Le9cR4FsRJcNO5z5f8AOvTbCME5AwO5NfO13bQ+kwsVa7NLSVkjUBSVGa6a0c8elZunCNyDwD061txQALuHQdq42z0FoX7UA5zyM9604NMjuE3OoJzVCx2sM8YrfsHGFIP4eooja4pvQyNU0KFYmDRKQw7DnNeJ+O/DsMdpcTxJzG4GB1yTivpGcLKhHWvJfF9kiahLHOrC3dxKW64xnitU7SOSqlKDPE7C1e0lSBg6hjzx94/4V1iKRpUO5CCx5PbNO1+zufMku7by3YkBCRwowMcUwzTPaRLcr5cmSWjAxtNetgVzVUzxMX7tNkSkgYyeKXknk5+tJThX0Z4wU9SQeCaaOTTqYDuuMnNKpIyBxSClBpiuSAnGMnHpSqeOCaRelOUUhXHEk8nNOHSminLQA8d80o4FIO1NuGKxHnAxzUzlyq5UY87sYPi28mWNbW3KGJwfOAPzEen06VzdraCdQAqs6jCgDA/D0q40TwTMdokdieN5OAetXrDSZZXSSBXQscjPavlsZiJVJtvQ+iwuG5YJIoWGkyPPth81ZM/wLkGuhh0OM/eeOWRT8ybCpz9P6g11Oh6K4XMrPuP4YrprfTbeGEBFC9+a82VU9WlhOrPN4ND8iXzDAoderegPoKbPYRNdsLK2N1t4KglR9QfT0rs9ftsRHa7BW4IUAfjnqPwrj5FkiMix/IP7zH5vrinTld3ZNejGKsjPmtY8lXsHtpIvvMjhxj9Oa0rayiuM7UbfGN7GYfcX+9x1z2WiaGG306KFmJuZDuw5yUXufr7mrMM22Ikb2LMGAAxk+pz2A/U1re5ycqRLBp73KoWQ/Z1AGN2GzngYJ5/XFZ2rQSjWXtUferfLMqksMdWBb8K393kRRshbzFjMr7TzHn7qj35pVt4rS3huIwu4qzFj83IOA3v1pqdgcVYyNIuo7N8TbooXGFUcIg/h+XHH1/OujGCMjGCMjFZup2tpCpN0biKQFXZ3bnPcjHX2FXbGX7RaRy4I3DOMY/SveyzEuX7pnjY+jb30TAU4D1oApQOa9g8wWloFKBQMBSijFKBSYBQKWlAoGOUU4DjmgDGKdSC40gYopx6UUgueCZ+XFPB4qHPFPB5rkNx4paappc+1MLDqUGm5ooAkzTwc8d6iFOU8U0wJRSimj60op3EPBqRTUIP5U8YqhMkU09TUa9KcppgiXtR3pob86UHimBKvAxWV4kjL28DDsxH6VqA8VFqaFtEuWClmDqoIH3c9TXLjHaizowkeaqkWvCsYstEikfrMTIf6fyrag8QvG3yWzEDr7irGl6clzpEcRyNqBRjqOKxNR0vV9Kn8y2lEtue0gOPx9K+ddpPU+i96mro6jSPFWnyzhJHMD9lb1r0DTb+OQfeBGzjHc14DqV5eylBLFAx/i2HP9K7v4ZG6urhFlLbF+UDr+NZzppK5rRrSlLlPVLKUA7QcZAOPrW5aXRRQQm4eteeeN7q48OmadZFAZVwu3JGO59BWH4f8Ya1etGY57ZoAfmG0qR7+lZqm2tDaVW2h7jE4aMsox64rj/HMajSZJWXIU8+tP0rV7pFVrgboW4Ei8/nTfG6/a/COpiPr5eVx2ORTUdTKck4s8Xj1SS3mniZyY9rADGcHsRSGeSfbJMcuVGfyqjGpa6V2GXMaseOB2NXEHAzX0eV0Uk6h83jpu/KP6inCmgU4A5r1zzhwFOpFpaBDqcKaKcP0piHCnj2poFOHWgBw6+1OHSmgGnjmgBygcZpxGRSCnDtSdrajV76GMlkJNUfJBRMfd6V01kqRuMD/AOtWbajam7Ay3JrTts7hkde/pXw2KqOpUbPusJTVOmkdJatwozzirYy5AJPv7VlWTYGDgk1sWoyy5POOlcljt5jD8RbkTaQSDwK44x/apo+TsJUsemRkjGe3Nd5rK+Y6sRxnH1rHvdL32yFBhjkAf7Q5rWGhw19WY13aoEmZEwXkWMcZDBTjHPbJzViK0hke6RnJgMnDZ67Rz+A9Kl1l2iGY/ursbI6q3Gf1qsNkAuAgMiICBg8liev/AOqtVc4nuaQhaSJgI0WGRAhPRg2chj+QFW/lYTPaAgQKYuB/FjofzxS2ZWfUgA+HMSo0ZPy5AB6VZS3+z6jHEi4WSQTOGPWQ9/1oEzMuLYysqbzuKrhcDcG2nnPtjiiK3e3VBJlmdAfM24BPcfrUwRi10Zv9Yhl2yHvliF/LtV/Ud4hiibcwVVfcTwWxg4rtwM3GvGxyYuKlSdzPHU04CgUoFfWnz1wFLRSigYfjTgBSU4dKTAAOadigdTSgZpALjpTyOMUg60/FIBpHFFOooA+fKUHFN70tcdzqFzUm6oqcKdxEi5I5pwpimnUXAUGnA0wU6mIkBp47VEOtSA8YpphYfSjrTQaWquIlFOFRrTx0piHinr1qOgHnmmJkv6Vp6MgneW2kAaF13Mp746YPaspcAcVLHI8bBkYq3TIOKyxFP2lJxOjC1fZVYzZ1WiXflAK30AxXQF47iLBQ9Oc965axQPGm3qBW1DI6kKcY/lXys1qfV0XeKRXv7SyZlBhBbgegFdR4Ct1+2SeUoGCqqBxXMXB3SoNyqvXP9BXoPw+t0W3aYgF/vYFQ7s2hFJto1PGOgrrtnKm1HU8FWGQQK850XwBcWd8bjTbh7ZwcExuV/NTwa9Xu7tYWVNxDsMj3qrkGQOCMnriqjU5VYzlR5tSjZaFJFFC1zdM8y9SoC7h6ECpPFjJaeGLsBgCQo5P+0K1I7qMNt25I71neIrSXV9PltoEjZzhl8w4UYPrQndkez05TzLX7MaFpVvYxtG01+izzlVBIUH7ufr/KudFa3iiaN9UW3t38yGyjFtvHR2BJdh7ZJH4Vk19bgafs6KT3Z8rj6nPWdtloOH61IKYOtOzXWcQ8Y4pR1po605etMQ4ClHSjtSrQA4dacKbTx0oEKKevWmrinimFxy9ac33Cfamj2pLtzDaSysDsUAnjtmsqz5acmuxpSSdSN+6CMHIGOMVp2rAEDdXOyahHHbiZWypOARzWZH4ogSYKWIwcfMQOa+HcHI+79rGCtc9SsFDMCRwP1rYiiyQAORyK4DQvEUcwHlSRyY4YI2cfWujPim1s8JLHLvI3KCu0kfj1/Ks/Zy2sV7eHc3bjThOp5weo+tYl8GsmPn52n5gT0JPWmLr2r3/zadYCJD0kuDgH8KdeaLqepaVcNqmqNI+MpFAgWMH1Pc1ahb4jGcuf4UcvqOoQlvIYMWLEkKDyBn9aoWrXEKPdLbhyowqyTKGJxzhRn8q6ix8MwecRNGXQBTlz975sn8hXWX2lRwWbRRxKkAO9VQYGPar9pGOiMI0JT+LQ5HSZWS2j1G/txAZyNsK/M+0DFdBCtpq9mmpWDSSC0dvPjl4ePIOD7jNct4gu7OLxN5fntA4ijGxx8jrjjb+vWuh8J2kkV9rqKcRXFisg9PvCs23e56EsPTdJ8q1RXih3wNmEMsiZ5OAFBz/h+NTatMrW1qgAOcsD3AxjFSiJHjlSKR/MRHjBPOPnz+fQVTvFYW8KgYWPKHI713YB/v4nz2LX7uRUHWnUgpR1r68+duKKUUUooAUUtIOlKKQCqKf6Ug6UopAOXpTgKQDinCkxhiijvRQB88g5+tKKb+dKPrXEdY6l7UgopoQ9actMp46+1MQ4UtIKWgB4pRTRTs00IepNPqJTTw2aYh+aeCcVGDThVIRLnikP0pBS1QhympFJxUQp6mnvoF7G/plwBjmtyKZM/OfeuNtJSrYHUVreZJcRbbdwr8Hn/Cvl8VScJtM+pwldTgmjY1e1j1CyMaOVbI2sOoNdR4De/tEl0+WdRcKu4EDOAehOeprgrH+3En/0KCyuihDbSxRm/A8V2+n65It4l3ceHr1Z5ECSiFSxTHoOhFc9mkdqfNqdeYbyWCL7XOtxPECd6rtyfpVuJWMQPTPase21y33pslYFzjbKhjcexBrdjkRlDL0POKxe5o3oNjQBsHrisbxX4mXw5FGqQedc3KP5a5wExxuP51uIdz8Y5ryHx7qQ1PxPceU2be2At4yDwcfeP55/KvQy6gq9W0tkeZmGIdGneO7MKMFV5OfU+pp45NMWnKa+sR8o+7JF4PNOXoaYKetMQ6lWkzTh1piFANOFIODTqAFFPXqaYtOpiHdKkFR5/KnjmgQ8daxbrSP7Q8QwwzFzbyqxBLt97HCjnitodOKSRGYI0b+XNGdyPjO0isa9N1IcqNqE1Cd2ZNnoT2V1NbXMguNNBzFC2Q24jILHuOox7in6ppkItRLFaQwEkhkCDA+hrp4ojqU0rSxhA4AKqTgfQ/WqlyZ4Ve1uEgZB90vkEjt0r5GpUtUaR9dTot0031Rx/hia+sJNSv7CONVlt1tbqJMByQ42yL7gYz9a6G1nvFkSTYkjt9/LeY6/8C/pWfLpWJ0beNgbdtA2jOMZ963NNVIV2rn3qKlW60FSwzjK7Oo0MyyriUsxHIzXURr+7A6gisTQ0GxGTvXRSYVEwDz1rjbuehBWKc9tIVBjhbeRjeK1L1W/shAchvlyf5ilgkzH169PajVkLaeIuS8nC46560mkWtzyHVbG88ReJdTl02MXdkJjtf7qqo9Cfoa7/wCH9pLPp17NuDBLcWyP1DEHJ/oKXQLaaL7RaXqOkMo27Cu0nIxwK7rQrCKx09beFQsYGOlNzua1ZKFNpdTiraFY4lEihXywfaf4vU/hgmsjWJV8uKJPu43D/GtzWM2ssowSpYgsTjHPpXK3coluXdSSucDJzxXsZRRc63P2PlcxnyQce5DSr1pKUCvqT58WlFApaBh2p4HamCnA5oAcOMU9aaBSqKQ0PHSnCmjpThUsAopaKQHzsOeKXvzSL1p2K4zsAU6kFFBI/HNL04o4o4zVCHjrS0zrTgaAH5pQaZmlFMQ8GnA1GDxTgeaAJRTgajX3p2R0FUhEqnOKdioweeacGqhWH0qnFNzSrTETQnM6gcE1o2i+ZlVYq/Y+9Z1s224jJ7NWjPG0U+5M4614+ZL316Hr5a7RZpWgu7ciQR5Y8cevrXb6Hc3qiMzqzAqMkHGDXL+H9QyfLfg9geld14e1BJVxtUc8140m0e3B+ZozSpPaGJ0ZskH5ucEVYtGYRKhGMcUT3kEYVQVDenpSW8zSfdX61g33NjStFBcHqAOa8R1/SpdF1m6s5ssA2+KQ/wDLSNuQ39PqK9vRhHDtB+dxjPt3rB8VaJba/ZhZCYrmDPkzKMlR3UjuDXoZdjFh6nvbM87MML7aneO6PIAeaeuB3rctNAQ3At7yS5WbcQTEFKEeoJ6fjXVWPhfQrJ0juVudSuiM7Q+1R9cV7s81w8Fvc8aOVYiVtDzwHrUijjrjNd7deD9HNww+03lrI3ItrcCYIPq1V0+HV9KSbe+tzH28xGDfjjinDNcNLeVvUmeV4iP2bnFge9OHFdpffDvUraykmt7iK5mQFjCqlSwHXae59q4sHoRXZRxNOur03c462HqUXaorXFHWnCkX7wFPfGeK3MQHSnCjHFA5JpiHrjNO7UxeafjAoAevrThTBz0p47UmBt6Q6RwKWOAe/wDWs3xc6LZpcxyKW3Y+Vsj2qEuVtpYycxsCSvbpWBotpCQk865ZfuZHANfIYrBSwz5pvc+0wmNhi1aCtYv28jyKN4xnqPStnT4ARjGD2PrVC2VXkcRqT/Wt7RwpGT0FcLfkdlrbnQ6ArL8jDp0PY1tXJLSbVxkcYrKsXWNiavx5L7mHy44rJlF2HO0ZHHXFX7B1ury3LEKI33jPbFZN3P5SY3YJ4BxVvRzhQxx05J9Kll23Rf1KIS65vUHO0Hjtmtu1IWMCsa3dppWkONznJJ7DtWtCCAMmovdk1I2ikYPjeFU0iSXC7QQOnqf/AK9eaCvWvFcP2jw1qcYwWWIvj6EH+leS+/avq8jt7KXqfLZzdVIhQKKUV7h4otL3pKUUhiinCmiloAkBpy9aYBSikA8U7NNFOHSpY2L3opM0UgPnjrThTM+lKCc8muM7B9FNzTgc0CaHZoBptFFyR+7HSnZ5qOnBsdqdwHinCmgj1pQfypiHClzTc0tAEinmn+mKhyaeDzVAS0oNR5HrTgeKdySQU8cCogRjk8Ve0/T7m8P7qMiPPMjDCj/Gk5xirsqMXPRIjgRpZVSNSzZ7V1kdoZoElX5gevtUNjYw20YWMEs/Bc9T/wDWrp/DVsGsQTgjJ614WPxSqtOOyPbwWHdJPm3ZjNZQqFLLhuuRwasWqmN9qTTf7qHFWNWUiUKq8+1WrC22qpbkmvPb0ud8XrY1NHgZiGclF/ug5Y/Vuv4CuohZIogABgdFAxWDakRIpJ5q4txk1zyu2bqVjREzOx/vetSZ+Xb2qpBliCelW+i8dqlOxSXMcnq9lqdrdS3OnTQFHXkSocj8R1qaymfS9LMkvN5KQoY9WY9wPStfUYkuoJIJiyow6o20/gawH0AJdRy2t9c7lBXEwEgAPp0wablc6octtTo7J4rCwFzcGSRmOTtXc7nGeB3PtVPQ/El7qFqupoiQW8oPlWzk+YqqSPm7Bu5HanQJLEFaSVpHXgFhjA9gOlNu7WC6YsU8uYnPmR8En1I6GiKVtQnJX8jpNL1e5u5FRQPNJyvYfSuG+I/hv7DePq1jHtsZ3/fxgY8iU+391j+ta2mxX2n3ImSRbgA8ADa3+FdxFJa61ZPFOoaORTHKhGMg9Qa6sDiZYWrzLbqedj8NDEQ5T585zQCe9WdWsW03VbywcktbStHk9wDwfyxVUHivt4yUoqS6nxk4uMmmSbs0ox0ptOXORVEEgGMd6eBmmE5NO+lMQ8U4+1MU85qQHd1oAO2COCMVkx2upfaZkt7mBLXOI43Qs35DpWypB684rL1MNBcRzQbiX+8o9u9eTm1NypcyWx7GT1lCq4PqQC01W2uEl822dVOSqqQT75rsbB/NxKnBkHzAdCe9c/btNLCWZSCPWtTRhJHExPY/nXy8nc+oasdAsp86JGIwa6CyIdmJx5aDJJPpXHJI0upEKQ6oABXR38httKjjU/vbg8j+dZSQ4sia5N1dE5OxmJ/4D2rW+07FSJCS7HgCsCW4j0yyEkhBk6KMck9lq54cgu7y5DGJ5Zm/5ZoM7R7nt+NS02VGSWrOwsOIgxySa1LWRpZRHGrSv3VRk/8A1qsaN4bZ9j6hOQP+eMJ4/Fu/4V19lb29nCI7eJIk9h1/xrejhHLWWiOTEZhBaQV2YP8AYc91HIJVSJJUKMGOTgjHQV5h438Ft4Xt7WeO6a7t5WMbMyBSjYyOnYgH8q9vnuooMBjlj0A5NUdX0m28QaeLbU4SbYusgUMQcg8civZwk1hnaO3U8TEt4he+fOHA68Uo6V9C2/hDw/AhWPSLPBGDuTcfzPNeD6xZtp+r31mwI8id4x9AeP0xXt0MVGs2ktjy6tB01dlKnL3pKFroOcdx60opB1pV60DJKBSelHrSAkHSjNNHSnVLGLRSDrRRYD54pQaSiuI7BSTTg2KZRQA/dmjd60yjpmgCUMDS5qIGnbqBND8nINPDetQ7xTsincViYEU4GoQ1ODUySUGnZqMNxS5poCTI9a2NK0O6vwrt+5gP8bDk/Qf1p/hXS1vZ/PnGYYzgA92ruWZYgOgArzsVjXTfJDc9HC4NTXPPYzbDRbGyAIhE0g/il5/TpVq4cyYROT0OOgpk8rOcA96tWMRO0AA5OK8ydSUtZO56lOklpFWGw2LMA5BwBW94fURaUQcD5zTxADFtxgUIot4lRei9q46k3JWOuFJRK8lr9om3Yzj09KlO2I4XJ9qljlZxtQFF6ZxjNXbezU8tkmpUrFeyT2KcSuxA9exq/BBtHPJq9HboPuiphFgdqTkUqaRWRyCAo47n0qyWGzuTUMkRByKGbbHyazbNVYYfmfn1qZUH1piqcc9TU6CpbDmEMIY5wM0Rwc+hq3GoIzxQFG6o5guNWPlAoHXmrcMZimWRWIIOCVHUVGACO31qRDgd8+1awlfcwqPscN8SdAvY9WutZhgaXTpgjvLH83lnAB3DsCR16VxIHFfSnha4iKzWk0av5mOHGVKDqmPqa86+JPw2k0oTat4djaXTeXmtV+Zrf1K+qe3UfSvrsvxqlCNOofK43DWm5RPMhThTRggEEEe1OHH4V655o5eoqQVGtSCmIUVJkDG3PvTBTqAJF9qr3w2xq/8ACp59qnHBp5z9Qe1Y4iiq1N031N8PWdCoqi6FW0vIndVdsAitj7THb27FWBB4UZ9axbjTo3UtB+6k/wDHSf6VnsZ7V91yj+zckV8ricvqUXqro+noZjTrrR2Z1mhHFwjsxx3OK1dT1SGGY3dxIBFCu1RjO4+3qe1cTba4N8dtZo891MdqRRclj7f416J4V8NNayRX+rlZ9QHMaDmO3/3fVv8Aa/KuL2d3qdEqyiiPw74cutYvY9S8Q77W3Azb2SnEmP7zn+H6da9V0xIrSBIbaNIoh0VBgf8A1/xrChIB5HPrSX2sWulpE17cpAZWCRIxy8rHoqKOWP0q0ktjiqVZT0O0ivEiX5iMUNeyz48nKKeM+v0rIsIXYiW6DIOuxuo+taSTrn90Bgd6ftZS0MeRI0LOLym3Ny5OcmtNZwSASBWCJGzktk0/7YAPkKs2OvUD/GumnNIlq50PUV4f8WrI2vi9pgMJdwrIPcj5T/IV6zaam7uqPEwP8TY+UH271z/j/wANN4mtknsZil/aKdkTn5HB5wfQnHB/OvQwdaMKib2ObEU3KDSPE6KmvLa4spzDeQS28w/glQqf/r/hUPfivdTT2PJaa3FFLSA0UwHgnNOFMB4NLnikMkU0oJPWmr0ozSEPopAeKKQz55opKARXEdgZozS5FNz7UrjsOzSE0lFK4WFyKcKj/ClzQ2Fh/QUZ4pueKQE5p3FYkDc04MKjBHfNLkZ44oTBolBp4JJGOp4FQBjV7R4vP1S3TsG3H6CiU+VNhGHM0j0HR4RZWEMQ4Krk+571ZLlie9VlYtwMYqzEnGST+FfOyd25PqfRQjokhFTLAYrasowAOlZ8ERJ9PTNa2nRliRkkqCTWMnc6IRsXoN0hVU5PuKLa33XzxyHJUg1c0CFnfzSMpyKivG+y6rcS4+VsYrnb1OlK509jo8dzalcfhWKwe1neKQHKNtzXdaBFm0jcEHcAazdWtIXv5FkUBnOfrQ3oUlryowoiABzU6ZOM1Lc6ZJAu5PmX0qFTkY5yOOlZsEPkUY5xVUqC30q0PmG0jt1pjLt59Ki4mRbcDNSRVFJIFOCaIn54PFFmIvpjFKD81Ro3FIDyaVgJsA4NSIahUkipUBBxWkFqRPYt2c7QXEcw/gYH8O9ehaddrLGpUg8Zx7V5spH4Vu6TqH+jx26ZE2cbu231+tenh5WR4+Jjrc5n4hfC9HE+q+FlIkJMkth2fuTF6Hvt/KvHQM9OMcEEc59K+s3uAgXB+UDO4HpXnPxM+H41dJNd8Oxj7fjdcWyjAuP9pR/f/n9a93C4y3uVDyK+HuuaJ4oopw4pB9CPY8EU4dK9Y4BR1p46UwdKcDTEPXrUnU1Gpp4NADhkUSzpbRSTSuqRRqXYk4GBRiuM8f6o6ummQjMa7Zbk5AyOy8/mawxFRU6bbNaEHOaSPWfhvYaXNpS61p6LJPeFhJMRyCDyg9AD2rspriCztZLm6ljgtoxl5ZWCqo9STXzz4J+KNv4Q8KXemLZSX979qaa2+YLCqsBu3EcnBHQdfWuH8W+L9Z8V3Hm63es8SnKW8fyQx/RR/M5NfLOk5Sbex73Okj13xv8AGyG3aSz8Hw/aps7ft0y5jH+4nVj7nj2rtfgl4T1K2abxT4xeS68SXikw/an+e1hPoDwrN6DoOPWuJ+BHw1eNofFHiC2O/htOtZF53HpKw/8AQR+Ne6T3Spe+SEEtyoCgnnb61lUlH4I/MFd6s3WwVVpJEAPT5hipIlaTPlD5R1bHFZEO7ILnzJO/OFFadrOqAgTy7mGCI+BWajG422SNPEnyu5LdD71JFfwKeMfnVmCCO5cO8ZYgYyy1qRWkOOYoyOmNorpjBPYybZQttQiZlyVx9OlbSkbNyhWXHUd6py6PZTDmAI396P5TVcWl5pp32zmeHuh64reKsSXL2xstVt2gvbeK4hPVJFzj6en4V5T498Bro1rJqWkM7WaH99A53NGP7ynuPY16vBIlztmg4YcOtWpUSaJ45FDxuCrKeQQeorejWlSd1sZzpxmrM+Xz14pRWr4t0g6F4gu7AAiJTvhJ7xnkflyPwrHFe9GSklJbM8mUXFtMkzQDTM+1KCaYEoPpS5qMHFLnikxD80U0GikM+e6KM0hPGa4DuFyAeaTPFNLUxqVx2JC3HFIW4pvX3pcckHtS6gKG7k/hSg89eKQ4K0gAIO00mx6DyaAaTJCnNI2c4PSi4iSjPFRk4xSg5ouIk3YrW8NH/iaL67DisbPrXQ+DbfzL+SUjIjXaPqaitK1N3NqEb1FY7i1iwoBA5q4iknHJqOBNwXHP9K0LaPJ447V8/KR9DGJJBGuBu49jV6E+VbSSDkkFapSyJGHToy8VT+1v9mCnoDyKizZpdRO48I3ETaUFJG4etVtcgMwby+T1rn9HuHtACpOwmulik86EydRmpdNJg6+isdP4dvZIbS1RgemDmtnUrJb3DLw4rD0iaKSJFOARXT2x4A/Wk0rWBVdeZFSzt2MXlS8445rJ8QWS2ksTx8B+CPeunLKpJrmPEd2JZ44gfunJqHFWGqrnIzEwacwyp4pi08tkfSsbGzZzuu3H2aS2QH5pHPHtirlo5ZFrG1M/b/ESBT+7tYzuPbc3QflWzZrtUVbVkLc0VHHvS9KWIZGak2ZFZ9QGoxJ5qQPUTDBApC2DWsTOZOZAB1rR0BhJdyg5yEyPasKV+OCaSy1A2lxvHIZSh5xwa76O55uIV0dzJP8Au/LRuM8nNdBpE2y2UMdoWvLxd3ErqzSNHH2APJrr/D1409vKvJZQCfpmumErtnDJcqOE+I3w91FvEM9/4ctTeWl4xlkijIDQyH73BIypPP515ve2txY3L2t7by21zH96KVdrD8PSvpmDVYlaZcbxEBlgeCSelcx8RvDV34xtLFtNFoLy3Ls0kxKlk7RggevPPAr1sPjWmoT2OGrh005Lc8HHXNOHapLy1uLK7mtb2GSC5hbbJE4wVP8AnvUYr1lZq6PPatox4604cGmp15pxOCScYpgZ3iTWU0PSJbxgGlJCQo3RnPTPsOteK3t5c307zXkzSyucsW7mus+Kd7JLrsFmWYRW8KtsPADtyT+WK4uvExlZznyrZHq4anywv1YuQBk9K99+E/wektpoNc8aJAigCS1093Dk9w8gGfwX86xPgt8N11QR+I/EMGdOQ7rO2cf8fDA/fYf3B2Hc+1e7NNNeT+VEwwOC3YCvLq1H8MTsjHuS6hL9qfybV5Pk5Dhio3evsB6VcsLVLKLarNLcSHdLIxyWP+FQQKEIihXgcse7H3rVtIHYgtnJ54rkfY19Sa1tjIQZTx/dBresbWJMHIPsBVK3jVDlo2I+la9tJZnAwY2962p03uzKUuxciUdjj2q3EvFNiVSAUKkdqnUY6jFdcVYzFXpS0UVQETQL5olX5X7kdx71Jjkn1paDQB518ZNHW50iHVol/fWZCufWNj/Q4P5147mvo/xfZm/8L6rbKPme3fH1AyP5V82q2VB9RmvXwE3Km4voefi42kmh+aAaj3UoNdxxkuTS54zURNGeKVhkoaiot1FKwzwIkUxjkmkJBNOwc4ArzTvG44OTzTgAKNuKN46D86m4xw6Z6UcZOajLZ7cmjdzzSuKxJxRwOKjDnnvQW4HuetAWJPyBpfYimBhk03fn/wDVSCw8gbqUjIwDgVEWJ6UpbPQ8Y700x2H4x/Ou68G223TVfHMrFj9K4NSWOM8ngAd816votsLe0giHVEArkxs7QsduBhed+xsWseAO/atGCLABNVbcZI7VeTIxt/GvFkz3ImD4kV4bhJVJ2ycH6imWp8yLJ7jn61raxbC8s2jH3x8yn3Fc/YT7W2ScEcEVrB3ic9a6kbNi/wC6ZWzgV1ul8afGPWuTsgr+YnqMiug8OXCsr2khxIvK5pSMY6s6TTVDLlTgiuisrl0ADfnXOWWbd+elb0RBUEdTzWDZ0LU1Gm3RFjwAOa4uaUy3EkjHqxxXTXBYWFxt+8Yzj64rBs4FezXcPmx1qJSXU1pKzIk5NVtTuxaW0jkjhTVySJoc8ZFcj4yuGNjKFyDjH5mlFamz3ItGJa389/8AWXDGVvx6fpW9AeBWVo8LXNxHBAM8AZPRRXbW3hiQRgs7Fu/pVum2ZSrRW7KFueKsg5HvV4aDcR/dOfqKifTbpCcpkVHs2mONaEtmUJMAE96rscVbkgmBI8tie/FUpiVOGBB9xVJWCTTW5DK+FNYWs3Hl23od4rWuJNq9a5PxHcYMSZ4LE/kK7KOpw4hWR0Oj34uIMuf3g42jkn3rqILtrS3RVb/SJuwPQV5x4cnG7IYAg59j7fjXVWV2JblLpt20NjB6it1aGpwyTlojto5vJt4ol4x8ze5NbA1SOx0xyXw2AoIGcEnFclLfRyOrRHIqG6uHnntIQfl8zzG99oJH6kUe0tqTydDc8RaNoGuMl1qlvNNerF5QZJimADkE46nnvXIxeD9EiuHVftdzGSNolk2lR6fL1+pq79pZEkunYk3Ei28C+i5wT+JyfwqNLordeaxIjWQjGeo6VrHG1UrJ6EvDwethZPBXhtjl5r+3A67JQwH5iqg0XSNCuJ7u2uJrmGOMt5l0igxgcnA/qa1LuQbSVO7cRXn/AMZtXOm+Ar0I2JbxltI8Hn5uWP4AH86r65VmuS4Rw0Iu9j588W6xJr/ibUtUlP8Ax8zFl9kHCj8gK6n4P+BD4w1tri+Vl0SxYNct/wA9m6iIfXv7fWuf8F+EdW8W6lDaaXbv5LPtkumX93Cvck+w7V9a+HPDtvoWjW2j6XAyWNuvX+KVj1cn1NRVnyq3U0jG7JZR5+23tgsVtEoQBRhVA6KKu2lriPbCML6nvVy30yYhdyBUHRBWzbWBIG8EAdsYri1ZrexX0fTGVWZRuPeteK1dCAqoD9KtWI+zjCg4rTRo5MFk5reFJNXMpS1KlvC2PnC1b+zwkfMgqZIo/wCEVJsFdKikZlSO2jX/AFTEe2atoCBhjmo2hB+6cN60oVwvXmqAloqNJD0cYIqSgAooooARgGUgjIPBr5c1KH7JqV5bf88ZnQfgxFfUlfMfiph/wkuqkdPtcv8A6Ea9LLnrJehx4xe6jNJo3VGWppbAr0zzyfdijfUAf1pN+TQMn3UVX30UDPDNozinFgB15pCSWAFM3cYryWd45m5POaiJzSk5ptIY4dKGOaQUUDCjPIzRRSAXNJRRQAZooooAs6eoe9j3NhQd31xXrFnIDHGc8lQa8gjfy3VxztOTXpWl3Qkt42Vv4Rg+1efjE3Zno4KaSaOpt5QCBWhG4xnPTisG1lPToa1IXyMA8V5sonpxZcYg+mfWsDU7Mh/OhXHqK3ME9O1QXA45x+FKDsxzXMjM024JYc/Op5Fac7SQypcwZ3LzWHMrW9yHjzgnpW7p9zHKoVuhFavXVHJZwdmdlompQ6lar8wEgHI962IpSkYUnpxmvNCJLCbzrVyAeSK6LSPEMd0oWUhXHWspQ6o2hI7Fb9TbyKWH3SP0rE07U45bdMMOlc/rWptaF5EbKY9a5TQddDl4d4Dxsce65yDXPOk5ao6ackmesi5RhgmsHXbSG+2WuCWlPGOKz4tU/dbsjpVrw3cC+1u4dsstsBznoTVUYPmCvUSg2df4X0eLSrWMYzKOrHnJ9a6ITEd81kRT4ADd+atxzqRjNbXd7nlOzNOKfIAp0tyM7cAj1qhI2xCVNRmUrb5PU0+dpE8pKk8XnkbF5PNay6RZ3kWXjU59q5PzSHJzXQaNqYCbGPNbU5K/vClzLZmTrvgQPG7adIVOPutyK80u/AupapeI/miLyNykBc5ya9se+lZyqHg1PYQrGjZALMcmtFKKleIpTk1aTPFrLwFeWKFGuC2Tn7lbVj4VvGKIspXZ3A+9Xe6v8rZFU9PuytwgY8ZrJ1OZ2YkranOapoN/pFuLhk82IfeKjkVkwzvL57RDcyrsBHOCeT/SvYr6UGIIyhkdeh5rjZ9OtrWRjDGNrHdjHerqKKskEW2czLCJ/skisPLtuidw3TmqJy11OgXO1ug7hutei6ZpFnqG+VolExHIHfFYdzbQrd5jQenT0rOWhSdypoGiXmpKkDNtVTw55O2qvxK+Dlt4nt7BLi/uYltiSqxkAEnGSQfYYr0Hwp8h4GAa1Nbc5CA9Oa2grQ5jNtt2PPNJ0O38NWUNjaWyQwxqFXYMA4962baUkZq/56NmK4UMh9ulOGnrt3W7Ar6VjJOWqLTsizpSGaZFJ461vNGsWBtGPXFYGls9tdLvRuuOldQwDDB6V1UF7uplLcp4jY1IIOPlORUU0BVuOlVjcSW7DqR6VtYi5o4K4qVc4qpb30cvDYDVcU5HtTQxMjvTgQaQgGkKDtmgBSoPWlAxTRkdadQAUUUh5P0oAWvlbW5S+tai56tcyH/x419U18m6o3/EyvcH/lvJ/wChmvSy77Xy/U5MX8KISaQmoy9Rs9emecT7qbu9TUJemF+c0DJ94oqsW5ooGeMls9QKQnJpKWvIZ6AUUUUrjCikoouAtFFFACUtJQB6dKAFopDRQAd66bwrdSJasGBMUb7VOeme1cqx4PNdl4VgH9jvuH+sJaufEtKGp04VNzOtsnLYNblsxA7ZxWBpiYiQnk4rbtz0rx5ns09jTVuADxmkdc9sioN4zwenvVqA7hzxWD0NdzMuLcMeQRWXIZLWbcudprp5Is5yOvFUbqzDptYZX+VXCpbcidPmKseorJFtc9etUrhvLfzIWwevBqneW7wzvEThgNy+4rOkuJI22yZ4re19jl1i7M0LzV5XRopjncMVyN3LJBcCaA7XXoR3rZuJFkHSsy5XIYAfjTSSG56G/o3iRbuPyJWCTY+mTXonw1Je3vZOryThT+ArwC/jaNhNExV15zXu3wdlM9ncyH7hZXH1K80OKim0TOo5Rsz0iRipHp0qNXJbg/rU7MpFRtGpb5axTuYsZPeOjqCTirn2xZIgPasi94Iz2qNJMAc8H0quVMV7Gq5DRnBFRW8218ZqGOXg9xUU2QCy9qaQN3OltrrBHNbVjPuPWuDhvCAAT0ra0zUAJF3Gmrol6mzqwyDXOmTZLn3rpLzE1sGFcvdjaxOahfExrY6/T5/ttiBnLoMCsvUUIyDWfoWpfZrpUY/KeDW9qsQePen3TzVTvpIUbLQq+G7wQXYVz8pNLq2n+RdzbR8rMWH0PNZVsrGRmTqK3LfUBdIILgfOvAPrTtzxsJuzNHwxH+6Jxjmr2txnakg9MGpLONba0BUYHWp5dt1Ztgg8ZFdfJ+7sZ3965x0wG8H3rVs4GCBkJBNZ1wpViO4bpXT6fEBChx1rGjG7KkySKMLhmAq4rBulIVBGMUwLg8V1pWMyYgEc1Wmt1kBqYNTgQaYbmBd2TxNuQcjpirGn3pyEkOD71rOoYYIrPuNOBO+M4bOaCbGiGyKUVBbbxHhxyKmoGLRRmkNAXFpD7UZ4pM5oAbK4jhkkPRVLH8BXyJPKZJpJCfvuzfmc19S+Mrwaf4U1a6Jx5ds+D7kYH6mvlHcQij0Ar1MuVoykceLeyJGamFqYzUwtXonASFuKbv8AWoiaazdaBkhf3oqBm4ooGkeS0tJSc1456AtA96BR3oGLSfSijNAAKU0g6+1GRQAYFLSEjpRmgBaacdKbySfSkbBHfIoGkI5/lXe6ENmlQrj+CuFtYjPcRxL1dgK75V8n5V6AVx4p7RO3Cq12buktmBfpW5CuAB261iaYCkCYxWzFJjqf0ryp7nqU9ibpmrlqeFNZsknIwM1ctJM9e1ZSRomaRXIzR5YZcnvSRsCBzTioY5HFZGyMfX9NNxGs8H/HxApKjP3h6GuWlWK7gBKlJBzg9RXeujYIrG1nShcxb7bEdwnIx0b2Na06ltGc9ajzK6OKRNrshpskJIwAKnmlG5o5kMcyHBHvUkMgdOuK6vM4mmjEvbB2QhV6j8q9a+Ddu1r4SJY/OZmGfYdK4RomZd3aus+GmpN9hvbIA/uJtwPsw/8ArU/iViJaK56X5+RgnkURy/MOayPtGQGGQad5p+VkYe9SqZlzlu8ly3JHNU3nKY9KguWkL9cimLGzL83NaKKQua5dgu8NzyKvJKGHBGCKw2jKnPapoZWQ9eKTS6Bc0ZV5JWmw3DRsDSRyh196hlBU57Ul2GdhouppLGYpD14BNN1O3xkryPauPhunt3V1JxXS2GrR3MWyQ8+9RKDWqGmZkwZHz0roNF1oNF5FxyMcGs+6gWQEpissBoZQR2NUveVheZ22nwoHlIwQ3SoGi8u+Q9Dmq2l3QKjmtCbDSo46jmtVFIzbuzpLiTFhkdQtU/D97+9aJzwTkUpmD2YweoxWXaQsk+5PwNatu5Jo6xZst8pQfK5BrooU2RKvoKzrUvKB5uDir4bNVGCi20DlckB4pMim5NLirEKQKaRzkGl7UZoAcrZHNLketQnJIxxSgGgCXNFNHUZp1ABRSE0ZoAcOlIRUTTBTwM/SlVnb+Db9aAucB8c7/wCyeCTbhsPeTpFjPVR8x/lXzuX69a9b/aGvt2paNYBs+VHJOyj1YhR/I14+xr2sFHlpJ9zzsU7zHFqYW5phambq6jnsPLUwtzTS1MJoHYcW96KhZu1FJsaR5j1NJkD2oBGcHrSN0wOe9eSd4uQaAaYDkDjn2p444oAM0h6/4U49aO1ACde9KehopuM5IPBoAByCetBbr2pAecUvBPWgYmeAO1NJ5AobqcdKSgpG14TtjNqRlYZWJc/ia667UjnHHrWd4RtvJsgzfef5jW5NGHGB9CK8ivV5qjPWoUuWmXdPO6FSOmK1IxlTWBpbMoMbEjacVuwEkDHcVzT3N4LQJMrjOalt3PFOcbgOM9qSNAG4yKhs0tY0YZQRxVqOYgdPpWcmQMA5HpUglKgDH61m43NFI0TICOagkYetVjMdw5qKSfA5NTyWL5zJ8SaYl8POiO25Uf8AfQ9K5EB4W7gg4INdpcXIII61hX0PnOWCkt3rppNpWZy1oKWqGWd2JcqxwQORVvwbqi6VrGoRyj5JQpH1rDKGOQkZBFPRytzHOV+dDz7itrW1OdRT0Z6n/bFuQOcZ7UqanGpI3cdua5Jru0mgQRsGOcgHqKapDNlWo9rboS8OujOzkvlI3KwzSLqJAFceHkUk7z+dH2iYDg0KouqM/q76M7M6iCOaaLwHpxXL2+oFRtlB+taEd7CcZcDPStY8stjKcJQ3N2O7IOQTVuO9DjDVhxMrDKtkVbjTPTg1TiluRc096sCOKizJC4KscZ4qFEYVKM7cGhWEadpqjqNshqy06SHIIrC4FTRSFTgUuVPULnRWc+wjBretLnzMc1xcM56VtaTdAsMGmkJnY2+Su3NXraLvVaw2vGGXnNaicBWFaJE3J4DjAAOam3lRnt0quWG7INSblx1GKoRY8wY4pwb2quJFAoaYj7q0DLHelyPSq3muegpyq56mgCcuopN4JqIrt5JoLqoySKAuTZozWf8Ab42yImDkdlOaqSalOXKJAR7sadgujcBpkgYrhSB71kwSXErAyPgegq/Gp7yE0CuSxIUOOKmqNUxySc0y9nW0s7i4f7kMbSH6AZotco+ZPixqTal4/wBWbI2QOLZMeiAZ/XNccx4qS7uXvLma6kYmSeRpWJ9WOarscCvooR5IqPY8mb5pNik0xjSFqYW4obEOJqJ2oLHFRM9JsYrNRUJaipbKPODgn+tBIptGT0rzUdthwPBz0pwYDOajo9u9BTRKKXj1qHPX1NLkkkmkKxIOaaScnBFJkZzyaTOV5GKBoMilzxk9qjPSloHYU+9OhQyTIn95sU3A5q3pChtRiyOAc1M3aLZUFeSR3OmYhiVV6AYrQBODkjmqNngx8cE96skgKee1eE9We2tEO01szytnq1dDBnAP6VzOmMfNcAd634iSgKttwecfxD0omhU2aAOcY5qVUPYfhVO3kJ56D+dXocORgCsWrG6dwxhu9P2M3G01YRQT2qxHHkcVHMWoma8R7DNQyQMRjB+tbJhGfemlBihSYchjLY7uWHNS/ZUQdB9avng1C54pXbCyRg6ppST5eMhZf0P1rnpo5rZ9s8ZA/vdjXcOMj1qncwB1IYAr6HpW0KjWjMp0lLVHLqsTYKgg+oq7EGXGGyKbdadsy0BIP93NU/OaNsOrKR61vpJaHM4uLszehQuORVhYlC8isu0uyy8Gr6zN5YzyazlFmkWht0EiQs2MAZrkNQv2luiYXKqvGQasa/qbPI1vG3AOGNYqjvXtZdg+X95P5Hj5hjOb93A2LTWry3I2ybh71s2/i6dAA6flXJjg0/8AGvUlh6ct0eWq811O8tfGa5AlVgPXFdDZa5BcqGR1Oe1eTKf/ANdTwyvHyjsv0Nc9TAQfw6GsMXL7R7HHcJIAQwqYMByTxXk8Gr3kS4WUn61u6P4jaUrBeH5icK3rXJUwU6av0OmGIhN2O+WVAmc81e0ybBDAng9KwrZGMoV8g5wc1tjZbRqxOOK49Dosd3pF4dm1WzxkCun0++jkAVuD3rzPQ7+Np1AcYrrYQzEMhPPpV3M3odkI42GRj8Kd5KAc1zsF1cIAvNSNqEiDMsgAHqaYze8uMDpSnaPSuM1Dxfa2akNNub0Brmm8bXmoXxggXyo+eT16UBY9SluoIRlpFA+tULzW4orWWdAXjjxuI7dq810i6uLrzDdTPIwbueldnpUYuLS6tSP9bEyj644/lQmJsRfEM14ZY7WPbIqF13fxY6iuW1u61C9h3NcOAOqIcA1JZXDWs8M44ZDnH862NTs0R454Rm2nG5COg9VNFxXOe8OavJa3IV8j+8v973+tejW2y9gWWFgQwrzTVtNZT50AwRzxWl4T117eXbIen3l/qKLjsmegwxbWwwwasKFycU+1mjuoVkQhgeQRUnlKDkcZphYVPuiuM+MOrHSfAGpPGcS3IFqhHbfwf0zXaAYryX9oy42eGtLt/wDnrd7v++VP+Na0I81WKYpu0WzwInHSmO3akZuajZq9255e45mqNm4pjNTC1JlDmaonakY8UxjUsaAtRUZPFFIDz6ikpa847wozRRSGLnGaTOTRRQADpzSClpKAFOOetBNFFABV/Q1zeg+g4qh6Vq+H1/fO2cDgZrGu7U2a0VeaOut22Jz1qSWTKEk9qqK+AoU/WllcFSMjmvIW56zehoach27umTwa14pgFwxPTFR6VFmNBjHHert4kUUZaVFAHc9qUpK5UIaXQy3kXseK0reQ5xXNWt7Y3F35MM6mTrsVucVv2kDYykhA9+aiSLjrsaaSbRkqSP8AZGato+4DGcVUiifZyV/lVpeB0rJo1TaJASMZobvTMk9AaRieKmwcw1+9R4yDxTy3FMyapRIciNhk1VmXANWwQe9V5jweciqSIcjOlHXis+5iWQEEAitCY+nWqbKWFapWJbuU4IGRsx4x6GpdSlePTrh1+VghPHariKFWs7XXC6XdEnHy4/M10UPemkznrvlg2jjclskkknqamTpzVdelTr0r6hLoj5h6kgNP61GOlOBrRGbJFqVW6VEppwpiJgeavaNGJtXsYz/FMufzrPB6Zrb8IxNN4ksFUdHLn2ABNZ13anJ+RpS1mkemTOBMWA7k1M0pePDHKntVEseMjBHDA1LH/qiB06ivk9T6BiW6vbzh4WYLnpXoOk6zHBZI1w4JAzXEIoPApZVyQpOQO1VGq1uZuCZ1Oo+MCSUtEJPTPasjU9Ru50QSSsu4ZIXisjb0HvV6+5kRR0Cir52ybJFHHDZOT61bssJrI7Zf+dVipCOcetTudmpqxGMOP6VcSWbmisRcyqe/NdxocxjuIm9TXCWP7vUH/EfrXZaYxABzjBBq1uQ0Z+t2n2bUbuLHyhyy/Q81teGXSbSZLaUeZGpJ2+n0pPFUG97a6UcSJ5bfUdKp+FbhbXUMSkBH+Q59SafUC5c2K7AYyJIHGUf1H+NcprGlyW0ontxgqc8V2luw0+8uLG5ObZmyp/u56GpbyxyCrYII4PqKBbGH4W1podockxk4Zf7prvMieJZI2yrDIrzO4sm0+8yB+7c/lXT+HdSMJ8iQ5Tt7Uxo6WMkrgnkV4d+0jNJ9t0GEt+42TOB/tZUfyr3NlDEMp4NeB/tKXCHWtEt1xvjt5JD9GYAfyNdWD/jL5mdb4GePOeeOlRs3rRu61ExzXrs4bAzc1GT60E801jzUjEY0wnmlJqNjSuAjtRUMjelFK4WOIooorgO4KKKKQBRRRQMKSlooGFFFFAgrY0IBVZzyWbAFY9bujR4tRgEsxz9K5sW7QN8OrzNuNgR6dvrUJlJkXPIBpScL0H0qq5ADZwAMnNeXFanoSZ3mkODGpHTArRkZCuZnOz+6B1rmdIvgbdcEbsVoyXbKg2HkHLH29KmcNTaE9C5baXaC6N0kMKyEdQoBrXhUKBkAYrKspRIvICt2XP61fWfC9cHuMZrNp9TWLSNGPGM57d6kyMdqpRyEnIINSedkDpS5SnMshsikLfl71CrHHFAbP0p8pm5DyeaY2efSjOM+tMZh607ESkMY5PpUEpwCKe7YPFUp5MZ55q0iHIrzNk4qIDmkJLGpFU4HGB/OqegLUbI20HvWF4lZjpjY6F1zWy4JzWVr6/8AEon9cqf1rpwn8RPzOfFr92zlFPSplqAVIpwa+lR82TjmlFNU8U4datEMeKeOlRAjPSpAabEyQYrqfh7EJNckdv8AVxW7Fj6ZIH9a5RfUV6J8NrbytMu7pwC08nlrn+6o/wATXJj6nJQl56HRhIc1VeR0twv2hjKP7oUkfxYHWmwkAH5XAPbFWTgZUcDHSoBxXzcXoe20OikwxLcAipWkBYYOfWkR8KMmomceZ0B+oppEsXd+8TqBnk1ank3T7s5B4qrbIjTcqMd6SQBXAHrVpEMkJ4kye2a0NTiMeoSKeDkcfgKyM/K2KvNI0jq7EsSAck1qiGbMbf6WD6gGuu0lgVH1Fclj5rZ/7w210mktjd60yWdXLAL3RZIv40+ZfwrkpYygJGQ2Rz75rstIceYVPQg1l65YeVHOwGQCGHsM1QiWcjUtMivAP3yDZKP61LpF6CBaXRyOiMe3tWXoF39nuDHL/qJRtYf1qzqlr9kkLYyucgj09aaAv6xp3mwkEDI6GuetyYpAD95TXVaPfrdRLFMwJx8revtWZ4h00wuLiIfL/FTE1c2rCbMC7vumvm749yzv8RbhZ0ZI47aJYc9GTBO4fjn8q9/0ubdpsg6lSK80/aF0j7X4c07WokzJZS+TMwHPlv0z7BsfnXThJKNTXqZVLyg0eB7sc1GzZNBPFMJ5r1mzjAmmGlJqNmqbjFY1C7cGlZuKiJzSARjRTGopCOOooorzzvCiiimAUUUUDCiiigGFFFFMQldVpkKQ26qOpGSSa5mABpkBGQWArrY8YRQoAPoK8/Gy2R24RbsbcSDcqr2HJrL1qbZYTspOWGAKu3DcE96xdUcvauG5GRXJTV2b1XodRYILWzs0XkSW8cgz3yOf1q4l2y+ZHI2WY5B6fhis3SZGm8NabJIcujGIH/Z9KsMBJHIW6qOK0mtSYPQ37C7ygVgeOa1kuN4GWHTBGK5Cy4YYNbdrIVAAxzz0rJxRvGTOhjlAYDLfl0qwp4H0/Osu3JAyCc5q7ESWOe1RY0TLaMeh4qTKhargkDNIrnAPFTYLkzvhcDk1XaXI6c0rk5pQgIzRsTa7K7MzHiq0kTN1rRYADoKjZQaOYfJ3KkUIH1qR4toyRVxVC9h9TVO7cnIqU7suySKMzAEjrXM+Jb+PYLNHBlbDMvoB60/xbqdxp+nPLbFRIeNxGcVwekOzzzvIxd25Zm5LH3r08FTXtE2edjqnuNI21NPU81Gn3QaeOtfQI8AnU9DTwc1ACeKlB4FUiWh4pwbmm0A81QrEoPGe1ereFo/I8N2Cdym8/ic15OxxG2Owr2CwASyt1XhRGgH5CvLzSXuRR3YBe82XpJP3mPaombAqKVj5tAY4rxkelcnVuKYX+egnAqAH95VogvWxwS1RyNubIp8RxE31qM9TTWwmKnQircfKqB/dqonU1ch/h/GqRJtg7reDHVTmt3TpAJGx3rAtjmFfrW1Z8McGmJnZ6XJiVG7HFbd1AlxEysOGG01zenE4Q/Suph5iWtARwT2slvcyRyDaYzjJ7/SuksHXULLyJuZUHBPcVf1C2hnGJY1bPr1FZpgW0uLd4SwOMcnOeaBGHfWt3pEzXFsDJb5y8f8AhXS6VqVvqlio3BlcbefX0PvVy8jVlbIyD1FcUq/2d4ljitSVinyXXtn1FURsdElqLWOVU+6zfpXNfEa9s7X4e6+b/DQPbNCoP8UjcKB755/CuplHmJGrE4L84r5v+N2v3994rn0iSRU0+wI8qFBgFiOWb1Nb4enzzREnZXPOemMkE0xj60ppjda9Y4thGNMY0E/MajY1IxC3NMNK3SmN0pC6iMaKaaKljP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper cut test is performed by a standing patient with their arm by their side and their shoulder in neutral position. The patient then flexes their elbow 90 degrees, supinates their arm, and makes a fist. Next, the patient rapidly brings fist to their chin, simulating a boxing &ldquo;upper cut&rdquo; motion, while the examiner resists this motion with their hand placed atop the fist. Pain or an uncomfortable popping sensation indicates a positive test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Courtesy of Stephen Simons, MD.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15905=[""].join("\n");
var outline_f15_34_15905=null;
var title_f15_34_15906="Patient information: Hyperkalemia (The Basics)";
var content_f15_34_15906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17129\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?3/26/3500\">",
"         Foods with low levels of potassium",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?9/17/9500\">",
"          Foods with high levels of potassium",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/28/6594\">",
"         Patient information: Lichen planus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/33/8722\">",
"         Patient information: Low-potassium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/41/42640\">",
"         Patient information: Low potassium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hyperkalemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hyperkalemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8473382\">",
"      <span class=\"h1\">",
"       What is hyperkalemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hyperkalemia is the medical term for &ldquo;too much potassium.&rdquo; Potassium is a substance found in certain foods. In people with hyperkalemia, the body holds on to too much potassium. People can get hyperkalemia if their kidneys are not working well, or if they take certain medicines.",
"     </p>",
"     <p>",
"      The medicines that can cause hyperkalemia include those listed below. Most of these medicines are used to treat high blood pressure or heart problems.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Angiotensin-converting enzyme inhibitors (called &ldquo;ACE inhibitors&rdquo;), such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30197?source=see_link\">",
"         enalapril",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=see_link\">",
"         captopril",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9734?source=see_link\">",
"         lisinopril",
"        </a>",
"       </li>",
"       <li>",
"        Angiotensin receptor blockers (called &ldquo;ARBs&rdquo;), such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?17/16/17669?source=see_link\">",
"         irbesartan",
"        </a>",
"        (brand name: Avapro&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?21/15/21749?source=see_link\">",
"         valsartan",
"        </a>",
"        &nbsp;(brand name: Diovan&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?26/43/27317?source=see_link\">",
"         Aliskiren",
"        </a>",
"        (brand name: Tekturna&reg;)",
"       </li>",
"       <li>",
"        Aldosterone antagonists, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=see_link\">",
"         spironolactone",
"        </a>",
"        (brand name: Aldactone&reg;)",
"       </li>",
"       <li>",
"        Certain beta blockers, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?42/4/43077?source=see_link\">",
"         propranolol",
"        </a>",
"        &nbsp;(brand name: Inderal&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?20/21/20821?source=see_link\">",
"         labetalol",
"        </a>",
"        (brand name: Normodyne&reg;)",
"       </li>",
"       <li>",
"        NSAIDs &ndash; You can buy certain kinds of NSAIDs at the pharmacy without a prescription. These include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        &nbsp;(brand name: Aleve&reg;). But for other kinds, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40949?source=see_link\">",
"         celecoxib",
"        </a>",
"        &nbsp;(brand name: Celebrex&reg;), you will need a prescription.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?29/34/30245?source=see_link\">",
"         Digoxin",
"        </a>",
"        (brand name: Lanoxin&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8473397\">",
"      <span class=\"h1\">",
"       What are the symptoms of hyperkalemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of hyperkalemia is a feeling of weakness in the muscles. The weakness usually starts in the legs and then spreads to the middle of the body and the arms. Hyperkalemia can also cause the heart to beat too slowly or too quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8473412\">",
"      <span class=\"h1\">",
"       Is there a test for hyperkalemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have hyperkalemia, he or she will do a blood test to measure the level of potassium in your blood. You might also have a test called an electrocardiogram or &ldquo;ECG.&rdquo; An ECG is a test that records the electrical activity of the heart.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8473427\">",
"      <span class=\"h1\">",
"       How is hyperkalemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, doctors treat hyperkalemia by recommending a change in diet or medicines.",
"     </p>",
"     <p>",
"      To treat your hyperkalemia, you will need to eat a diet that has very little potassium. This means you will need to eat more low-potassium foods (",
"      <a class=\"graphic graphic_table graphicRef63021 \" href=\"UTD.htm?3/26/3500\">",
"       table 1",
"      </a>",
"      ) and fewer high-potassium foods (",
"      <a class=\"graphic graphic_table graphicRef67156 \" href=\"UTD.htm?9/17/9500\">",
"       table 2",
"      </a>",
"      ). Your doctor can refer you to a dietician (food expert) who can help you plan meals that are low in potassium.",
"     </p>",
"     <p>",
"      If your hyperkalemia was caused by one of your medicines, your doctor might also decide to lower the dose of the medicine or to switch you to a medicine that is less likely to cause hyperkalemia.",
"     </p>",
"     <p>",
"      If you have severe hyperkalemia, you might need treatment with medicines that go into one of your veins through an &ldquo;IV.&rdquo; Often, the IV goes in a vein in your arm. But sometimes, the IV needs to go through a large vein in your chest or groin. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8473442\">",
"      <span class=\"h1\">",
"       Can hyperkalemia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have kidney disease, you can reduce your chances of getting hyperkalemia by eating a low potassium diet. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8473457\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=see_link\">",
"       Patient information: Low-potassium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=see_link\">",
"       Patient information: Lichen planus (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=see_link\">",
"       Patient information: Low potassium diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/34/15906?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17129 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-124.240.187.81-3C54767836-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15906=[""].join("\n");
var outline_f15_34_15906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8473382\">",
"      What is hyperkalemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8473397\">",
"      What are the symptoms of hyperkalemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8473412\">",
"      Is there a test for hyperkalemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8473427\">",
"      How is hyperkalemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8473442\">",
"      Can hyperkalemia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8473457\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17129\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/26/3500\">",
"      Foods with low levels of potassium",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?9/17/9500\">",
"       Foods with high levels of potassium",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=related_link\">",
"      Patient information: Lichen planus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=related_link\">",
"      Patient information: Low potassium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=related_link\">",
"      Patient information: Low-potassium diet (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15907="Membranous and infundibular VSDs";
var content_f15_34_15907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Parasternal echocardiographic views of a membranous ventricular septal defect and an infundibular ventricular septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Parasternal short axis echocardiographic view with color flow Doppler demonstrating a membranous ventricular septal defect with a left-to-right shunt in proximity to the tricuspid valve (TV) (turbulent flow from LV to RV).",
"    <br/>",
"    (B) Color flow Doppler demonstrating infundibular ventricular septal defect in the right ventricular outflow tract in proximity to the pulmonary valve (PV).",
"    <div class=\"footnotes\">",
"     AO: aorta; LA: left atrium; PA: pulmonary artery; RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes CA (Ed). &copy; 2009 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15907=[""].join("\n");
var outline_f15_34_15907=null;
var title_f15_34_15908="Etomidate: Drug information";
var content_f15_34_15908=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etomidate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/22/32099?source=see_link\">",
"    see \"Etomidate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"    see \"Etomidate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amidate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amidate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anesthesia: I.V.: Initial: 0.2-0.6 mg/kg over 30-60 seconds for induction of anesthesia; maintenance: 5-20 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procedural sedation (unlabeled use): I.V.: Initial: 0.1-0.2 mg/kg, followed by 0.05 mg/kg every 3-5 minutes as needed (Bahn, 2005; Miner, 2007; Vinson, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"      see \"Etomidate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;10 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amidate&reg;: 2 mg/mL (10 mL, 20 mL) [contains propylene glycol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2364901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. push over 30-60 seconds. Solution is highly irritating; avoid administration into small vessels; in some cases, preadministration of lidocaine may be considered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F169169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, atracurium, atropine, ephedrine, fentanyl, lidocaine, lorazepam, midazolam, morphine, pancuronium, phenylephrine, succinylcholine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ascorbic acid, vecuronium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction and maintenance of general anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F169159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedation for diagnosis of seizure foci; procedural sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F169171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Etomidate may be confused with etidronate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting on emergence from anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site (30% to 80%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myoclonus (33%), transient skeletal movements, uncontrolled eye movements",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Hiccups",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apnea, arrhythmia, bradycardia, decreased cortisol synthesis, hypertension, hyperventilation, hypotension, hypoventilation, laryngospasm, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etomidate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal steroid production: Etomidate inhibits 11-B-hydroxylase, an enzyme important in adrenal steroid production. A single induction dose blocks the normal stress-induced increase in adrenal cortisol production for 4-8 hours, up to 24 hours in elderly and debilitated patients. Continuous infusion of etomidate for sedation in the ICU may increase mortality because patients may not be able to respond to stress. No increase in mortality has been identified with a single dose for induction of anesthesia. Consider exogenous corticosteroid replacement in patients undergoing severe stress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;10 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13763473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13763474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amidate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (20 mL): $19.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Etomidate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (10 mL): $10.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac monitoring and blood pressure required",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F169126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Etomidat-Lipuro (CH, LU);",
"     </li>",
"     <li>",
"      Etomidato-Lipuro (AR);",
"     </li>",
"     <li>",
"      Hypnomidate (AT, BE, BG, BR, CH, CZ, DE, ES, FR, GB, GR, HR, IE, LU, MX, NL, PL, PT, PY, RU, TR, TW, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ultrashort-acting nonbarbiturate hypnotic (benzylimidazole) used for the induction of anesthesia; chemically, it is a carboxylated imidazole which produces a rapid induction of anesthesia with minimal cardiovascular effects; produces EEG burst suppression at high doses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-5 minutes; terminated by redistribution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-4.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and plasma esterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 2.6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bahn EL and Holt KR, \"Procedural Sedation and Analgesia: A Review and New Concepts,\"",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2005, 23(2):503-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/15829394/pubmed\" id=\"15829394\" target=\"_blank\">",
"        15829394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ding Z and White PF, &ldquo;Anesthesia for Electroconvulsive Therapy,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 94(5):1351-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/11973219/pubmed\" id=\"11973219\" target=\"_blank\">",
"        11973219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hildreth AN, Mejia VA, Maxwell RA, et al, &ldquo;Adrenal Suppression Following a Single Dose of Etomidate for Rapid Sequence Induction: A Prospective Randomized Study,&rdquo;",
"      <i>",
"       J Trauma",
"      </i>",
"      , 2008, 65(3):573-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/18784570/pubmed\" id=\"18784570\" target=\"_blank\">",
"        18784570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miner JR, Danahy M, Moch A, et al, \"Randomized Clinical Trial of Etomidate Versus Propofol for Procedural Sedation in the Emergency Department,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(1):15-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/16997421/pubmed\" id=\"16997421\" target=\"_blank\">",
"        16997421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vinson DR and Bradbury DR, \"Etomidate for Procedural Sedation in Emergency Medicine,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2002, 39(6):592-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15908/abstract-text/12023700/pubmed\" id=\"12023700\" target=\"_blank\">",
"        12023700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8428 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15908=[""].join("\n");
var outline_f15_34_15908=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169137\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169163\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169139\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169150\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169140\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881402\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881403\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169120\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169106\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2364901\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169169\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169121\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169159\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169171\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169161\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169124\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169110\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299304\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169115\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169117\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763473\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763474\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323138\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169118\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169126\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169109\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169123\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8428|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/22/32099?source=related_link\">",
"      Etomidate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=related_link\">",
"      Etomidate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15909="Brompheniramine and pseudoephedrine: Pediatric drug information";
var content_f15_34_15909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brompheniramine and pseudoephedrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36645?source=see_link\">",
"    see \"Brompheniramine and pseudoephedrine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/18/38180?source=see_link\">",
"    see \"Brompheniramine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brotapp [OTC];",
"     </li>",
"     <li>",
"      J-Tan D PD [OTC];",
"     </li>",
"     <li>",
"      Lodrane&reg; D [OTC];",
"     </li>",
"     <li>",
"      LoHist PSB [OTC];",
"     </li>",
"     <li>",
"      Q-Tapp Cold &amp; Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine/Decongestant Combination",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36645?source=see_link\">",
"      see \"Brompheniramine and pseudoephedrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral liquid (brompheniramine 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL): Manufacturer's recommendation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-11 years: 10 mL every 6 hours (maximum: 40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 20 mL every 6 hours (maximum: 80 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternative pediatric dosing: May dose according to the pseudoephedrine component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;4 years: 1 mg/kg/dose every 6 hours; maximum single dose: 15 mg (Gentile, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-5 years: 1 mg/kg/dose every 6 hours; maximum single dose: 15 mg (Gentile, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 30 mg every 4-6 hours; maximum dose: 120 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 30-60 mg every 6 hours or extended release product 120 mg every 12 hours; maximum dose: 240 mg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lodrane&reg; D: Brompheniramine maleate 4 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brotapp: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL (120 mL, 240 mL, 480 mL) [ethanol free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     LoHist PSB: Brompheniramine maleate 4 mg and pseudoephedrine hydrochloride 20 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Q-Tapp Cold &amp; Allergy: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL (118 mL, 237 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     J-Tan D PD: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 7.5 mg per 1 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol; cotton candy flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of nasal congestion, running nose, sneezing, and itchy, watery eyes; also promotes nasal or sinus drainage (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F142696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, flushing, hypertension, pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Convulsions, CNS stimulation, dizziness, excitability (children; rare), giddiness, hallucinations, headache, insomnia, irritability, lassitude, nervousness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention (with BPH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular skeletal: Tremors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory difficulty",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brompheniramine, pseudoephedrine, or any component; MAO inhibitor therapy (or 2 weeks following MAO inhibitor use)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild-moderate hypertension, heart disease, arrhythmias, diabetes mellitus, thyroid disease, asthma, glaucoma, and prostatic hypertrophy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported (in some cases, high blood concentrations of pseudoephedrine were found). The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient. Antihistamines may cause excitation in young children. When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual monograph for Pseudoephedrine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Brompheniramine component only:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: Maximal clinical effects seen within 3-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Varies with formulation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual monograph for Pseudoephedrine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Brompheniramine component only:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Extensive by the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life: 12-34 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: In urine as inactive metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/18/38180?source=see_link\">",
"      see \"Brompheniramine and pseudoephedrine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gentile DA, Friday GA, and Skoner DP, \"Management of Allergic Rhinitis: Antihistamines and Decongestants,\"",
"      <i>",
"       Immunol Allergy Clin NA",
"      </i>",
"      , 2000, 20(2):355-68.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13095 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15909=[""].join("\n");
var outline_f15_34_15909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142680\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056975\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056969\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142653\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056978\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142696\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056983\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056968\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056967\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298891\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218606\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056981\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056982\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056974\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36645?source=related_link\">",
"      Brompheniramine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/18/38180?source=related_link\">",
"      Brompheniramine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15910="Lomustine: Pediatric drug information";
var content_f15_34_15910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lomustine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"    see \"Lomustine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/60/8133?source=see_link\">",
"    see \"Lomustine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CeeNU&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CeeNU&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent (Nitrosourea)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"      see \"Lomustine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Repeat courses should only be administered after adequate recovery of leukocytes to &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (refer to individual protocol):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 75-130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose every 6 weeks; subsequent doses are readjusted after initial treatment according to platelet and leukocyte counts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 100-130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose every 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     With compromised marrow function: Initial dose: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose every 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment based on hematologic response (nadir) for subsequent cycles:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Leukocytes &gt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &gt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Leukocytes 2000-2999/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets 25,000-74,999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 70% of prior dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Leukocytes &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 50% of prior dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     The FDA-approved labeling does not contain renal dosing adjustment guidelines. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aronoff, 2007: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% to 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 25% to 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     The FDA-approved labeling does not contain hepatic adjustment guidelines; lomustine is hepatically metabolized and caution should be used in patients with hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CeeNU&reg;: 10 mg, 40 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with fluids on an empty stomach and at bedtime; do not administer food or drink for 2 hours after lomustine administration to decrease incidence of nausea and vomiting. Standard antiemetics may be administered prior to lomustine if needed. Varying strengths of capsules may be required to obtain necessary dose. Do not break capsules; use appropriate precautions (eg, gloves) when handling; avoid exposure to broken capsules.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Avoid exposure to excessive heat (&gt;40&deg;C; 104&deg;F) and prolonged exposure to moisture; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of primary or metastatic brain tumors; combination therapy of Hodgkin's disease in patients who relapsed while being treated with primary therapy or who failed to respond to primary therapy [FDA approved in pediatric patients (age not specified) and adults]; has also been used in the treatment of colon cancer, medulloblastoma, and melanoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomustine may be confused with bendamustine, carmustine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomustine should only be administered as a single dose once every 6 weeks; serious errors have occurred when lomustine was inadvertently administered daily.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F189645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, disorientation, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis; nausea and vomiting, usually within 3-6 hours after oral administration. Administration of the dose at bedtime, with an antiemetic, significantly reduces both the incidence and severity of nausea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bone marrow dysplasia, leukemia (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myelosuppression, common, dose-limiting, may be cumulative and irreversible; leukopenia (nadir: 5-6 weeks; recovery 6-8 weeks); thrombocytopenia (nadir: 4 weeks; recovery 5-6 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased, hepatotoxicity, kidney size decreased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, optic atrophy, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia (progressive), renal damage, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary fibrosis, pulmonary infiltrates",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lomustine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with depressed platelet, leukocyte, or erythrocyte counts; reduced dosages are recommended. Use with caution in patients with hepatic impairment; reversible hepatotoxicity (transaminase, alkaline phosphatase, and bilirubin elevations) has been reported; monitor liver function tests periodically. Kidney damage has been observed; azotemia, decreased kidney size, and renal failure have been reported with long-term use; use with caution in patients with renal impairment; monitor renal function tests periodically; dosage adjustment may be required. Should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Since major toxicity is bone marrow suppression, monitor blood counts weekly for at least 6 weeks after a dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; nadir: ~6 weeks; do not give courses more frequently than every 6 weeks because the toxicity is delayed and cumulative. May cause delayed pulmonary toxicity (infiltrates and/or fibrosis); usually related to cumulative doses &gt;1100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; onset of toxicity of 6 months or longer (has been reported up to 17 years after childhood administration in combination with radiation therapy); patients with baseline forced vital capacity (FVC) or carbon monoxide diffusing capacity (DL",
"     <sub>",
"      co",
"     </sub>",
"     ) &lt;70% of predicted levels are at particular risk. Lomustine has been found to be clastogenic, teratogenic, embryotoxic, and carcinogenic in animals. Long-term use may be associated with the development of secondary malignancies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F189633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid concurrent administration of food/drugs that cause vomiting",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects and embryotoxicity have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid pregnancy and should be advised of the potential harm to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, hepatic and renal function tests, pulmonary function tests (forced vital capacity, carbon monoxide diffusing capacity)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA and RNA synthesis through DNA alkylation and DNA cross-linking; carbamoylates amine groups on proteins; inhibits DNA polymerase activity, RNA and protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete absorption from the GI tract (30-60 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed; lomustine and/or its metabolites penetrate into the CNS; CSF level is &ge;50% of concurrent plasma concentration;  metabolites are present in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid conversion to 4-hydroxy metabolites (active) partially by liver microsomal enzymes during first pass through the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (metabolites): 16-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration (of active metabolite): Within 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted primarily in urine as metabolites; &lt;5% fecal excretion",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/60/8133?source=see_link\">",
"      see \"Lomustine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wear gloves when handling lomustine capsules. Notify physician if fever, chills, sore throat, bleeding, bruising, dry cough, swelling of feet or lower legs, shortness of breath, mental confusion, or yellowing of the eyes or skin occur; avoid alcohol and aspirin (GI irritants) for short periods after taking lomustine. Women of childbearing potential should be advised to avoid becoming pregnant while taking lomustine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 97, 177.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15910/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jakacki RI, Yates A, Blaney SM, et al, \"A Phase I Trial of Temozolomide and Lomustine in Newly Diagnosed High-Grade Gliomas of Childhood,\"",
"      <i>",
"       Neuro Oncol",
"      </i>",
"      , 2008, 10(4):569-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15910/abstract-text/18497327/pubmed\" id=\"18497327\" target=\"_blank\">",
"        18497327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medical Research Council Brain Tumor Working Party, \"Randomized Trial of Procarbazine, Lomustine, and Vincristine in the Adjuvant Treatment of High-Grade Astrocytoma: A Medical Research Council Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(2):509-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15910/abstract-text/11208845 /pubmed\" id=\"11208845 \" target=\"_blank\">",
"        11208845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer RJ, Gajjar A, Vezina G, et al, \"Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(25):4202-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/34/15910/abstract-text/16943538/pubmed\" id=\"16943538\" target=\"_blank\">",
"        16943538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12560 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15910=[""].join("\n");
var outline_f15_34_15910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709019\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048314\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048307\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189575\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189559\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048318\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048310\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048317\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136824\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189645\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048321\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048306\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048305\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189568\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048323\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189571\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189583\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048313\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048304\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048320\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048312\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=related_link\">",
"      Lomustine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/60/8133?source=related_link\">",
"      Lomustine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15911="Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices";
var content_f15_34_15911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Valluvan Jeevanandam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Howard J Eisen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15911/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/34/15911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulatory assist devices were initially designed to support patients in hemodynamic collapse, but are now used for a wide range of clinical conditions ranging from prophylactic insertion for invasive procedures to cardiogenic shock or cardiopulmonary arrest. There are three major types of percutaneous devices (as well as surgically-implanted ventricular assist devices [LVAD]):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Counterpulsation devices (intraaortic balloon pump and noninvasive counterpulsation)",
"     </li>",
"     <li>",
"      Cardiopulmonary assist devices (Cardiopulmonary support or CPS)",
"     </li>",
"     <li>",
"      Left ventricular assist devices (eg, Impella)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intraaortic balloon (IABP) is the most commonly used mechanical support device. It has a long clinical record of success, is simple, is inserted easily and rapidly, is the least expensive of all the devices, and does not require constant monitoring by technical support personnel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of cardiopulmonary and short-term ventricular assist devices will be reviewed here. The possible role for intermediate- and long-term devices as \"bridges\" to transplantation or as replacement therapy for failing hearts is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY ASSIST DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this device is used infrequently in the cardiac catheterization laboratory, percutaneous cardiopulmonary support (CPS) provides full cardiopulmonary support (including hemodynamic support and oxygenation of venous blood) analogous to that provided by bypass during cardiac surgery. The Bard CPS involves placement in the central arterial and venous circulation of large bore catheters that allow positioning of cannulae in the aorta and right atrium (",
"    <a class=\"graphic graphic_figure graphicRef52390 \" href=\"UTD.htm?34/11/35007\">",
"     figure 1",
"    </a>",
"    ). Blood from the venous catheter is pumped through a heat exchanger and oxygenator, and then returned to the systemic arterial circulation via the arterial cannula. CPS requires continuous, highly technical support. The CPS system is for short-term use (hours).",
"   </p>",
"   <p>",
"    Newer extracorporeal membrane oxygenation systems (ECMO) systems, using magnetic levitated centrifugal pumps and long term membrane oxygenators, can be used for longer periods of support (days to weeks). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Extracorporeal membrane oxygenation'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiopulmonary assist device has limited use outside the cardiac catheterization laboratory because of the delay between the acute event and achievement of full cardiopulmonary support [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/1\">",
"     1",
"    </a>",
"    ]. It is most effective in a catheterization laboratory that is already prepared for insertion and technical support. The CPS may be used in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute hemodynamic deterioration such as cardiogenic shock and cardiopulmonary arrest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-risk percutaneous transluminal coronary angioplasty (PTCA)",
"     </li>",
"     <li>",
"      Fulminant myocarditis presenting with cardiogenic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, one study initiated CPS in eight patients because of cardiogenic shock for 30 to 180 minutes due to acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/3\">",
"     3",
"    </a>",
"    ]. Two patients were in cardiac arrest, the remainder had a mean blood pressure of 43 to 55 mmHg before the bypass. The patients in cardiac arrest regained consciousness while still in ventricular fibrillation or asystole. One patient had left main, four had multivessel, and four had single vessel coronary disease. Seven patients had successful angioplasty of 15 of 16 attempted lesions. One patient had lesions unsuitable for either bypass or angioplasty and died. The remaining seven patients were alive at a mean follow-up of 8.2 months.",
"   </p>",
"   <p>",
"    Another multicenter registry experience evaluated 105 patients (mean age 62 years) undergoing high-risk PTCA (ejection fraction &lt;25 percent, target vessel supplying more than half the myocardium, or both) which was performed using CPS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/4\">",
"     4",
"    </a>",
"    ]. The cohort included 20 patients whose disease was deemed too severe to undergo bypass surgery, and 30 patients who had dilation of their only patent coronary vessel. Fifteen patients underwent dilation of the left main coronary artery. Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest pain and electrocardiographic changes were infrequent despite prolonged balloon inflations.",
"     </li>",
"     <li>",
"      The angioplasty success rate was 95 percent.",
"     </li>",
"     <li>",
"      Morbidity was common and usually due to arterial, venous, or nerve injury associated with cannula insertion or removal.",
"     </li>",
"     <li>",
"      The in-hospital mortality rate was 7.6 percent, although one-half of these patients were over the age of 75 and had left main coronary disease; in-hospital mortality dropped to 2.6 percent if these patients were eliminated.",
"     </li>",
"     <li>",
"      Three patients died of cardiac complications over the 12-month follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CPS may be instituted prophylactically, or used as standby for high-risk procedures. One study, for example, investigated 569 patients who underwent high-risk PTCA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/5\">",
"     5",
"    </a>",
"    ]. There were 389 patients in the prophylactic CPS group (catheters inserted and bypass initiated prior to PTCA), and 180 patients in the standby group (preparations made, but bypass not initiated prior to PTCA). Thirteen patients in the standby group sustained irreversible hemodynamic compromise; CPS was successfully initiated in twelve of these patients within five minutes. The overall procedural success was 88.7 percent for the prophylactic group and 84.4 percent for the standby group.",
"   </p>",
"   <p>",
"    Major complications did not differ between the two groups. However, femoral access site complications or the requirement of blood transfusion were more frequent in the prophylactic cohort (42 versus 12 percent in the standby group). Thus, standby CPS affords comparable success and major complication rates with a lower morbidity. The only exception was in patients with an ejection fraction &le;20 percent; this subset had a higher mortality in the standby group (19 versus 5 percent in the prophylactic group).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPS is contraindicated in the following clinical conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant aortic regurgitation",
"     </li>",
"     <li>",
"      Severe peripheral artery disease",
"     </li>",
"     <li>",
"      Bleeding diathesis",
"     </li>",
"     <li>",
"      Recent CVA or head trauma",
"     </li>",
"     <li>",
"      Uncontrolled sepsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local vascular (arterial or venous) or neurologic complications are most common because the cannulae are large. These complications initially occurred in approximately 12 percent of patients, with almost one-half requiring surgical treatment. Recent revisions in technique have decreased the major complication rate to only 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the reported experience comes from a small number of centers; these improvements may not be widely applicable at less experienced centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SHORT-TERM VAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many short-term ventricular assist devices (VADs) available. Unfortunately, their use has not resulted in many patients being discharged from the hospital. This is more a function of the high-risk patient population for which these devices are used than the mechanical efficiency of the pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Centrifugal pumps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Centrifugal pumps are an extension of cardiopulmonary bypass. They use rotating cones or impellers to generate energy that is recovered in the form of pressure flow work. There are presently two centrifugal pumps available, the Bio-Medicus (Bio-Medicus Inc, Minneapolis, MN) and Sarns",
"    <span class=\"nowrap\">",
"     (Sarns/3M",
"    </span>",
"    Ann Arbor, MI). The Bio-Medicus and Sarns are very short-term pumps used primarily for CPB during open heart cases. There are currently two magnetically levitated centrifugal pumps for ventricular assistance (the Thoratec CentraMag and TandemHeart). They cause less trauma, less heat generation, and are standard of care for short-term VAD support. They can be implanted for up to a month. Both have the capability of supporting patients who cannot be weaned from cardiopulmonary bypass or who are waiting cardiac transplantation. The pumps are versatile and can be used as a right ventricular assist device (RVAD), left ventricular assist device (LVAD) or biventricular (BiVAD) support.",
"   </p>",
"   <p>",
"    Insertion of centrifugal pumps generally requires a sternotomy. The right and or left atrium can be cannulated by using simple purse string sutures. The aorta",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the pulmonary artery are cannulated by using standard cardiopulmonary bypass aorta cannulae placed through a purse string suture. These devices can also be placed percutaneously in the catheterization laboratory.",
"   </p>",
"   <p>",
"    Centrifugal pumps have several important limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flow is nonpulsatile which can be reflected in poor end-organ function, specifically renal dysfunction.",
"     </li>",
"     <li>",
"      The devices are traumatic to blood, causing a significant amount of hemolysis and a generalized inflammatory response. However, with each newer generation, less trauma to blood is noted.",
"      <br/>",
"      <br/>",
"      Patients with centrifugal pumps should be maintained on continuous intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      which is begun as soon as the initial bleeding subsides and continued until device removal. The activated partial thromboplastin time is maintained between 150 and 200 seconds but can be reduced if flows are maintained and if bleeding increases.",
"     </li>",
"     <li>",
"      Patients are unable to ambulate or exercise with the device in place.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, centrifugal pumps are quite effective for short-term support during cardiopulmonary bypass. However, long-term use of these devices poses serious problems; the success rate when used for patients who cannot be weaned from cardiopulmonary bypass is only 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extracorporeal pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Abiomed biventricular system (BVS 5000) and the more recent AB5000 version were designed as alternatives to centrifugal pumps for short-term support. The pump is an extracorporeal device which has an atrial chamber that is filled by gravity drainage. Blood from the atrial chamber flows across polyurethane valves to a ventricular chamber where it is pneumatically pumped back to the patient. The reported total duration of support with this system has varied from one to forty-two days.",
"   </p>",
"   <p>",
"    Simplicity and ease of use are the primary advantages of this device. Outflow is through a coated graft into the pulmonary artery or the aorta. As a result, this device can be used in LVAD, RVAD, or BiVAD configurations. The devices are more expensive than centrifugal pumps, but can be maintained with minimal personnel. The console of the device basically has an",
"    <span class=\"nowrap\">",
"     on/off",
"    </span>",
"    switch with the flows being driven by the amount of drainage received by the atrial chamber. Thus, if flow decreases, the patient needs volume resuscitation to increase filling of the device.",
"   </p>",
"   <p>",
"    The extracorporeal pump has a low incidence of hemolysis. However, heparinization is essential since clots can form along the polyurethane valve surface, on the outflow cannula, or at the tip of the atrial cannula where it enters the left atrium.",
"   </p>",
"   <p>",
"    The extracorporeal pump is associated with a 30 percent success rate if it is used in a postcardiotomy situation to wean from cardiopulmonary bypass after intraaortic balloon pump insertion. It allows recovery of end organs and, in the United States, is approved for postcardiotomy use. If the native heart does not recover, a long-term device can be used as a bridge to transplantation. A particularly useful niche for the device is for donor heart dysfunction following transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Axial flow pumps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axial flow pump works on the principle of an Archimedes screw. The inflow is placed retrograde across the aortic valve into the left ventricle; a pump revolving at high speeds draws blood out of the left ventricle and ejected into the ascending aorta beyond the end of the pump (",
"    <a class=\"graphic graphic_figure graphicRef77754 \" href=\"UTD.htm?41/26/42404\">",
"     figure 2",
"    </a>",
"    ). Thus, there is active drainage, but with nonpulsatile flow and a low level of hemolysis.",
"   </p>",
"   <p>",
"    A device that uses this principle is the Impella microaxial flow device, which is a miniature impeller pump located within a catheter. Impella was designed for either surgical placement via a graft in the ascending aorta or for percutaneous placement via the femoral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 24 patients who received a surgically implanted Impella device for postcardiotomy failure, mortality was 54 percent, comparable to that seen in a cohort of high-risk patients supported with an intra-aortic balloon pump [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/6\">",
"     6",
"    </a>",
"    ]. A moderate degree of hemolysis and thrombocytopenia have been reported with this device [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PROTECT II trial was designed to compare outcomes in over 600 symptomatic patients with complex 3-vessel or unprotected left main coronary artery disease and severely depressed left ventricular function (left ventricular ejection fraction &le;35 percent) who were to be randomly assigned to an Impella (version 2.5) or an intraaortic balloon pump [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/8\">",
"     8",
"    </a>",
"    ]. The trial was stopped for futility at 69 percent of planned enrollment. There was no significant difference in the primary end point of major adverse events at 30 days (35.1 versus 40.1 percent, respectively).",
"   </p>",
"   <p>",
"    The potential role for Impella in patients with acute cardiogenic shock after myocardial infarction is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H26#H26\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Other mechanical devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Percutaneous left atrial-to-femoral-arterial VAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A percutaneous left atrial-to-femoral arterial VAD (Tandem Heart&trade;), with a venous catheter inserted into the left atrium by transseptal puncture and an arterial cannula inserted into the iliac artery for the return of blood, can be positioned within 30 minutes. The role of this device for short-term stabilization until recovery of jeopardized myocardium or as a bridge to definite surgical treatment was evaluated in 18 patients with cardiogenic shock due to a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/9\">",
"     9",
"    </a>",
"    ]. After a mean of four days of assistance, cardiac index improved from 1.7 to 2.4",
"    <span class=\"nowrap\">",
"     L/min/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and there was a significant increase in mean blood pressure and reduction in pulmonary artery, pulmonary capillary wedge, and central venous pressures.",
"   </p>",
"   <p>",
"    A subsequent randomized trial compared this device to an intraaortic balloon pump in 41 patients with cardiogenic shock after an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/10\">",
"     10",
"    </a>",
"    ]. Although hemodynamic and metabolic parameters were more effectively reversed with the VAD, complications such as severe bleeding and acute limb ischemia were more common and there was no difference in 30-day mortality (VAD 43 percent versus balloon pump 45 percent).",
"   </p>",
"   <p>",
"    An observational study evaluated outcomes in 117 patients with severe refractory cardiogenic shock treated with percutaneous VAD for an average of 5.8 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/11\">",
"     11",
"    </a>",
"    ]. Severe refractory cardiogenic shock was defined as a systolic blood pressure of &lt;90mmHg, a cardiac index of &lt;2.0",
"    <span class=\"nowrap\">",
"     l/min/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and evidence of end-organ failure despite pressor",
"    <span class=\"nowrap\">",
"     support/IABP",
"    </span>",
"    support (82 percent had received an IABP). Fifty-six (48 percent) of patients underwent cardiopulmonary resuscitation immediately before or at the time of implantation. Eighty patients had coronary artery disease (five with acute ST elevation MI) and 37 patients had nonischemic cardiomyopathy. The cardiac index improved from median of 0.52 to 3.0",
"    <span class=\"nowrap\">",
"     l/min/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    following VAD implantation. Mortality was 40.2 percent at 30 days and 45.3 percent at six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of patients enrolled in the Society of Thoracic Surgeons (STS) database between 1995 to 2004, three common indications for post-operative VAD implantation were found [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H13\">",
"     'Outcomes'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       VAD/cardiac",
"      </span>",
"      transplant backup in patients undergoing high risk surgical procedures, such as CABG or valve",
"      <span class=\"nowrap\">",
"       repair/replacement",
"      </span>",
"      in patients with poor preoperative left ventricular function. These patients usually required VAD support of the left ventricle alone and often ended up with cardiac transplants.",
"     </li>",
"     <li>",
"      Patients with unanticipated post-operative cardiac dysfunction who required mechanical support with VAD support of the right ventricles or less commonly both ventricles. Most of these patients would be supported to myocardial recovery with cardiac transplantation being a rare option.",
"     </li>",
"     <li>",
"      Post-operative cardiogenic shock in patients with acute myocardial infarctions who underwent emergent CABG. Early implementation of mechanical support resulted in relatively good outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVAD is contraindicated in the following clinical conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aortic regurgitation or prosthetic aortic valve",
"     </li>",
"     <li>",
"      Aortic aneurysm or dissection",
"     </li>",
"     <li>",
"      Severe aortic or peripheral vascular disease",
"     </li>",
"     <li>",
"      Left ventricular or left atrial thrombi",
"     </li>",
"     <li>",
"      Bleeding diathesis",
"     </li>",
"     <li>",
"      Uncontrolled sepsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the STS report discussed above, the outcomes of 5735 patients who had ventricular assist devices (VADs) implanted after cardiac surgery over a ten-year period from 1995 to 2004 were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/12\">",
"     12",
"    </a>",
"    ]. Survival to hospital discharge improved from 38.5 to 59.1 percent with a reduction in stroke, renal failure and bleeding. More current information comes from a study of outcomes of Medicare (USA) beneficiaries who received VAD support within 30 days of open-heart surgery between 2000 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/14\">",
"     14",
"    </a>",
"    ]. Among 1467 postcardiotomy patients, 34 percent were discharged alive with a device.",
"   </p>",
"   <p>",
"    The Medicare study also reported on longer-term outcomes. Of those patients discharged alive, 48 percent were readmitted within six months and 77 percent were alive at one year. Overall one year survival was 31 percent in the postcardiotomy group. At one year, 4 percent had undergone heart transplantation, 9 percent had a device removed and 24 percent were alive with a device. Mean one-year Medicare payments for inpatient care was $111,769.",
"   </p>",
"   <p>",
"    The above two studies identified predictors of poor outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      STS data base [",
"      <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/12\">",
"       12",
"      </a>",
"      ]: Preoperative need for dialysis and performing VAD implantation as an urgent salvage procedure or reoperation, myocardial infarction, aortic stenosis, female sex, race, peripheral vascular disease, New York heart Association Class IV heart failure, cardiogenic shock, left main coronary artery disease and valve procedures.",
"     </li>",
"     <li>",
"      Medicare beneficiaries study [",
"      <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/14\">",
"       14",
"      </a>",
"      ]: Low hospital implantation volumes, peripheral vascular disease, valvular heart disease, and geographic region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common and potentially fatal complication of the LVAD is infection. The rate of infection was examined in a retrospective review of 76 patients who underwent LVAD implantation as a bridge to cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/15\">",
"     15",
"    </a>",
"    ]. LVAD-related infection was diagnosed in 38 patients (50 percent); 29 bloodstream infections (including 5 cases of endocarditis) and 17 local infections. Among the patients with infection, continuous antimicrobial treatment before, during, and after transplantation was associated with fewer relapses than was a limited course of antibiotics (2 of 23 compared to 7 of 12 with a limited antibiotic course). Infection did not preclude successful transplantation. A second smaller study had similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to the susceptibility to infection. In addition to the presence of a foreign body, the LVAD may impair T cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical irritation of the left ventricle produces ventricular arrhythmias in over 25 percent of patients.",
"     </li>",
"     <li>",
"      Left ventricular thrombus and thromboembolic complications occur in 10 to 16 percent; risk factors for the development of thrombus include myocardial infarction before device implantation, left atrial cannulation, and postimplantation bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?15/34/15911/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=see_link\">",
"       \"Left ventricular thrombus after acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytopenia is seen in 7 percent.",
"     </li>",
"     <li>",
"      Some degree of hemolysis occurs in most patients, but is generally not severe enough to be a significant problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EXTRACORPOREAL MEMBRANE OXYGENATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal membrane oxygenation (ECMO) removes carbon dioxide from and adds oxygen to venous blood via an artificial membrane lung (",
"    <a class=\"graphic graphic_picture graphicRef54620 \" href=\"UTD.htm?39/57/40851\">",
"     picture 1",
"    </a>",
"    ). The pulmonary circulation is bypassed, and oxygenated blood returns to the patient via an arterial or venous route. With venovenous bypass, ECMO is effective primarily as a therapeutic option for patients with severe respiratory failure. With venoarterial bypass, an extracorporeal pump is employed to support systemic perfusion, thus providing a hemodynamic support option in patients with cardiac failure. The use of ECMO in this setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link&amp;anchor=H6#H6\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link&amp;anchor=H7#H7\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\", section on 'Relative contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ECMO using improved oxygenators and pumps are commonly used in the post cardiotomy situation for recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384154364\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulatory assist devices were initially designed to support patients in hemodynamic collapse, but are now used for a wide range of clinical conditions ranging from prophylactic insertion for invasive procedures to cardiogenic shock or cardiopulmonary arrest. There are three major types of percutaneous devices (as well as surgically-implanted ventricular assist devices [LVAD]):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Counterpulsation devices (intraaortic balloon pump and noninvasive counterpulsation). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"       \"Intraaortic balloon pump counterpulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiopulmonary assist devices (Cardiopulmonary support or CPS).",
"     </li>",
"     <li>",
"      Short-term left ventricular assist devices (VAD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiopulmonary support devices are used in the following circumstances (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Cardiopulmonary assist device'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute hemodynamic deterioration such as cardiogenic shock and cardiopulmonary arrest.",
"     </li>",
"     <li>",
"      High-risk percutaneous transluminal coronary angioplasty.",
"     </li>",
"     <li>",
"      Fulminant myocarditis presenting with cardiogenic shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short-term ventricular assist devices are used in the following circumstances (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Short-term VAD'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      After cardiac surgery to support patients who cannot be weaned from cardiopulmonary bypass.",
"     </li>",
"     <li>",
"      In the cath lab, as a bridge to cardiac surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Important contraindications and complications exist for each device type. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/1\">",
"      Hill JG, Bruhn PS, Cohen SE, et al. Emergent applications of cardiopulmonary support: a multiinstitutional experience. Ann Thorac Surg 1992; 54:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/2\">",
"      Kato S, Morimoto S, Hiramitsu S, et al. Use of percutaneous cardiopulmonary support of patients with fulminant myocarditis and cardiogenic shock for improving prognosis. Am J Cardiol 1999; 83:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/3\">",
"      Shawl FA, Domanski MJ, Hernandez TJ, Punja S. Emergency percutaneous cardiopulmonary bypass support in cardiogenic shock from acute myocardial infarction. Am J Cardiol 1989; 64:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/4\">",
"      Vogel RA, Shawl F, Tommaso C, et al. Initial report of the National Registry of Elective Cardiopulmonary Bypass Supported Coronary Angioplasty. J Am Coll Cardiol 1990; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/5\">",
"      Teirstein PS, Vogel RA, Dorros G, et al. Prophylactic versus standby cardiopulmonary support for high risk percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1993; 21:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/6\">",
"      Siegenthaler MP, Brehm K, Strecker T, et al. The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a three-center experience. J Thorac Cardiovasc Surg 2004; 127:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/7\">",
"      Jurmann MJ, Siniawski H, Erb M, et al. Initial experience with miniature axial flow ventricular assist devices for postcardiotomy heart failure. Ann Thorac Surg 2004; 77:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/8\">",
"      O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation 2012; 126:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/9\">",
"      Thiele H, Lauer B, Hambrecht R, et al. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001; 104:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/10\">",
"      Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/11\">",
"      Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 2011; 57:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/12\">",
"      Hernandez AF, Grab JD, Gammie JS, et al. A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database. Circulation 2007; 116:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/13\">",
"      Marelli D, Shemin RJ. Post-cardiac surgery mechanical support: a tool for decision making. Circulation 2007; 116:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/14\">",
"      Hernandez AF, Shea AM, Milano CA, et al. Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA 2008; 300:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/15\">",
"      Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 2005; 40:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/16\">",
"      Herrmann M, Weyand M, Greshake B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997; 95:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/17\">",
"      Deng MC, Erren M, Tjan TD, et al. Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Thorac Cardiovasc Surg 1999; 47 Suppl 2:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15911/abstract/18\">",
"      Reilly MP, Wiegers SE, Cucchiara AJ, et al. Frequency, risk factors, and clinical outcomes of left ventricular assist device-associated ventricular thrombus. Am J Cardiol 2000; 86:1156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1492 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15911=[""].join("\n");
var outline_f15_34_15911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H384154364\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIOPULMONARY ASSIST DEVICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SHORT-TERM VAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Centrifugal pumps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extracorporeal pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Axial flow pumps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Percutaneous left atrial-to-femoral-arterial VAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EXTRACORPOREAL MEMBRANE OXYGENATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384154364\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1492|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/11/35007\" title=\"figure 1\">",
"      Cardiopulmonary bypass support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/26/42404\" title=\"figure 2\">",
"      Left ventricular assist device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1492|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/57/40851\" title=\"picture 1\">",
"      Membrane oxygenator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15912="Enterobius eggs";
var content_f15_34_15912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Enterobius eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Eggs of",
"    <em>",
"     E. vermicularis",
"    </em>",
"    in a cellulose-tape preparation.",
"    <br/>",
"    (B) Eggs of",
"    <em>",
"     E. vermicularis",
"    </em>",
"    in a wet mount.",
"    <br/>",
"    (C) Egg of",
"    <em>",
"     E. vermicularis",
"    </em>",
"    in an iodine-stained wet mount from a formalin concentrate.",
"    <br/>",
"    (D) Eggs of",
"    <em>",
"     E. vermicularis",
"    </em>",
"    viewed under UV microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Enterobiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/enterobiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/enterobiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15912=[""].join("\n");
var outline_f15_34_15912=null;
var title_f15_34_15913="Accidental hypothermia in adults";
var content_f15_34_15913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Accidental hypothermia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15913/contributors\">",
"     C Crawford Mechem, MD, FACEP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15913/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15913/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15913/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/34/15913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death from exposure and accidental hypothermia occurs throughout the world and can present significant management problems [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. While typically associated with regions of the world with severe winters, hypothermia is also seen in areas with milder climates, such as the southern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/5\">",
"     5",
"    </a>",
"    ]. Cases of hypothermia occur during the summer months and in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/6\">",
"     6",
"    </a>",
"    ]. Even with modern supportive care, the in-hospital mortality of patients with moderate or severe accidental hypothermia approaches 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition, pathophysiology, and management of accidental hypothermia will be discussed here. A table outlining the emergency management of hypothermia in adults is provided (",
"    <a class=\"graphic graphic_table graphicRef51697 \" href=\"UTD.htm?29/46/30445\">",
"     table 1",
"    </a>",
"    ). The syndrome of near-drowning, which is often complicated by hypothermia, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=see_link\">",
"     \"Drowning (submersion injuries)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia is defined as a core temperature below 35&ordm;C (95&ordm;F) and can be further classified by severity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild hypothermia &ndash; Core temperature 32 to 35&ordm;C (90 to 95&ordm;F)",
"     </li>",
"     <li>",
"      Moderate hypothermia &ndash; Core temperature 28 to 32&ordm;C (82 to 90&ordm;F)",
"     </li>",
"     <li>",
"      Severe hypothermia &ndash; Core temperature below 28&ordm;C (82&ordm;F)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body temperature reflects the balance between heat production and heat loss. Heat is generated by cellular metabolism (most prominently in the heart and liver) and lost by the skin and lungs via the following processes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaporation &ndash; Vaporization of water through both insensible losses and sweat",
"     </li>",
"     <li>",
"      Radiation &ndash; Emission of infrared electromagnetic energy",
"     </li>",
"     <li>",
"      Conduction &ndash; Direct transfer of heat to an adjacent, cooler object",
"     </li>",
"     <li>",
"      Convection &ndash; Direct transfer of heat to convective air currents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, convective heat loss to cold air and conductive heat loss to water are the most common mechanisms of accidental hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothermia causes altered cell membrane function, efflux of intracellular fluid, enzymatic dysfunction, and electrolyte imbalances (including prominent hyperkalemia). Cell death results from cell membrane damage, protein dysfunction, or crystallization of intra- and extracellular water [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In response to a cold stress, the hypothalamus attempts to stimulate heat production through shivering and increased thyroid, catecholamine, and adrenal activity. Sympathetically mediated vasoconstriction minimizes heat loss by reducing blood flow to peripheral tissues, where cooling is greatest [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to hypothermia from environmental exposure, many medical conditions can result in hypothermia, including hypothyroidism, adrenal insufficiency, sepsis, neuromuscular disease, malnutrition, thiamine deficiency, and hypoglycemia. Ethanol abuse and carbon monoxide intoxication have been implicated in some cases of hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain medications directly or indirectly cause hypothermia, either by impairing thermoregulatory mechanisms, decreasing awareness of cold, or clouding judgment. The most common medications that impair thermoregulation are anxiolytics, antidepressants, antimanics, antipsychotics, and opioids. Medications that can impair a patient's ability to compensate for a low ambient temperature include oral antihyperglycemics, beta-blockers, alpha-adrenergic agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ), and general anesthetic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of hypothermia is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef58684 \" href=\"UTD.htm?16/46/17133\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9,14-19\">",
"     9,14-19",
"    </a>",
"    ]. Risk factors associated with death from accidental hypothermia include ethanol use, homelessness, psychiatric disease, and older age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. Frostbite and local cold-related injury are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General findings and progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the compensatory mechanisms preventing hypothermia are overwhelmed, the following changes typically occur (",
"    <a class=\"graphic graphic_table graphicRef55728 \" href=\"UTD.htm?22/40/23180\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild hypothermia demonstrate tachypnea, tachycardia, initial hyperventilation, ataxia, dysarthria, impaired judgment, shivering, and so-called \"cold diuresis.\"",
"     </li>",
"     <li>",
"      Moderate hypothermia is characterized by proportionate reductions in pulse rate and cardiac output, hypoventilation, central nervous system depression, hyporeflexia, decreased renal blood flow, and loss of shivering. Paradoxical undressing may be observed. Atrial fibrillation, junctional bradycardia, and other arrhythmias can occur.",
"     </li>",
"     <li>",
"      Severe hypothermia can lead to pulmonary edema, oliguria, areflexia, coma, hypotension, bradycardia, ventricular arrhythmias (including ventricular fibrillation), and asystole [",
"      <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9,21\">",
"       9,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At patient presentation, beware of vital signs inconsistent with the degree of hypothermia. A relative tachycardia inconsistent with temperature suggests hypoglycemia, hypovolemia, or an overdose. Relative hyperventilation implies an underlying organic acidosis (eg, diabetic ketoacidosis), since CO2 production should be decreased in moderate or severe hypothermia.",
"   </p>",
"   <p>",
"    Neurologic manifestations vary widely. If the level of consciousness is not proportional to the degree of hypothermia, suspect a head injury, central nervous system infection, or overdose. Do not assume that areflexia or paralysis is due to hypothermia until spinal injury has been ruled out. Hypothermia can be misdiagnosed as psychiatric illness, including attempted suicide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Geriatric population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elderly are at increased risk of developing hypothermia and its complications, and should be urgently assessed if found to be hypothermic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. The reasons for this increased risk include decreased physiologic reserve, chronic diseases and medications that impair compensatory responses, and social isolation. Hypothermia may go unrecognized in isolated older patients, and they may be unable to obtain assistance when the condition is recognized.",
"   </p>",
"   <p>",
"    In elderly patients sepsis can manifest as hypothermia. Empiric, broad spectrum antibiotics should be administered if there is an obvious source of infection, aspiration, failure to rewarm, or other signs suggestive of sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination and temperature measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothermic heart is very sensitive to movement, and rough handling of the patient may precipitate arrhythmias, including ventricular fibrillation. Take care to avoid jostling the patient during the physical examination or the performance of essential procedures.",
"   </p>",
"   <p>",
"    The proper diagnosis and management of hypothermia depend upon the use of a low-reading glass or electronic thermometer to determine core temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Many standard thermometers only read down to a minimum of 34&ordm;C (93&ordm;F) and are therefore unsuitable in this situation.",
"   </p>",
"   <p>",
"    A rectal probe thermometer is practical in most cases. In patients with severe hypothermia, particularly those requiring endotracheal intubation, an esophageal probe provides a near approximation of cardiac temperature. Either device may be inaccurate: rectal probe readings may rise following peritoneal lavage or fall if adjacent to cold feces; esophageal probe readings may rise due to warm air transmitted through the trachea. The reliability of tympanic thermometers in the setting of significant hypothermia has NOT been established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A total body survey should be conducted in all hypothermic patients to exclude local cold-induced injuries in areas not seen during the initial resuscitation and to assess for signs of trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory studies and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After making the diagnosis, laboratory evaluation should be undertaken to identify potential complications and comorbidities, including lactic acidosis, rhabdomyolysis, bleeding diathesis, and infection. Previously healthy patients with mild accidental hypothermia may not require laboratory investigation. We obtain the following tests in cases of moderate and severe hypothermia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fingerstick glucose",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG)",
"     </li>",
"     <li>",
"      Basic serum electrolytes, including potassium and calcium",
"     </li>",
"     <li>",
"      BUN and creatinine",
"     </li>",
"     <li>",
"      Serum hemoglobin, white blood cell, and platelet counts",
"     </li>",
"     <li>",
"      Serum lactate",
"     </li>",
"     <li>",
"      Fibrinogen level",
"     </li>",
"     <li>",
"      Creatine phosphokinase",
"     </li>",
"     <li>",
"      Arterial blood gas, uncorrected for temperature",
"     </li>",
"     <li>",
"      Chest radiograph (care must be taken to avoid jostling the patient)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are obtained based on clinical circumstances. As an example, a toxicologic screen might be obtained in a patient with a depressed mental status incommensurate with the core temperature. A serum cortisol and thyroid function studies might be obtained in a patient with moderate or severe hypothermia who fails to rewarm despite aggressive interventions. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Failure to rewarm'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the hematocrit increases 2 percent for each 1&ordm;C drop in temperature, a low normal hematocrit is abnormal in severe hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/24\">",
"     24",
"    </a>",
"    ]. Hyperglycemia that persists during rewarming suggests pancreatitis or diabetic ketoacidosis. Remember that insulin is ineffective below 30&ordm;C. Hypothermia obscures normal premonitory ECG changes commonly associated with hyperkalemia.",
"   </p>",
"   <p>",
"    A list of characteristic laboratory abnormalities is provided (",
"    <a class=\"graphic graphic_table graphicRef67294 \" href=\"UTD.htm?29/13/29915\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9,12,14,19,21,25,26\">",
"     9,12,14,19,21,25,26",
"    </a>",
"    ]. Rewarming can be accompanied by rapid or unpredictable changes in electrolyte concentrations, so frequent reassessment of these parameters (approximately every four hours) is prudent in moderate and severe hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of the enzymes of the coagulation cascade from hypothermia leads to a bleeding diathesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/25\">",
"     25",
"    </a>",
"    ]. Because tests of coagulation (eg, prothrombin time, partial thromboplastin time) are always performed at 37&ordm;C, the laboratory will report deceptively \"normal\" results despite an obvious in vivo coagulopathy. Treatment consists of rewarming; administration of clotting factors is ineffective.",
"   </p>",
"   <p>",
"    Oxygenation should be monitored continuously; however, the response time of pulse oximeters placed on the finger is slowed by hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/27\">",
"     27",
"    </a>",
"    ]. Probes placed on the ears or forehead appear to be less influenced by decreased body temperature and the associated peripheral vasoconstriction. Assessment of oxygenation is also complicated by the fact that arterial blood gas analyzers operate at 37&ordm;C, which is (by definition) greater than the body temperature of a hypothermic patient.",
"   </p>",
"   <p>",
"    The pH, PCO2, and PO2 of a blood sample all vary with the temperature, as gas tensions and hydrogen ion concentration decline as temperature drops [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Use uncorrected values to guide therapy, recognizing that these results correspond to the arterial blood gas values that would have been present if the patient's temperature were 37&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/28\">",
"     28",
"    </a>",
"    ]. An uncorrected pH of 7.40 and a pCO2 of 40 mmHg reflect acid-base balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link&amp;anchor=H11#H11\">",
"     \"Arterial blood gases\", section on 'Analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electrocardiographic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent of the arrhythmogenic complications noted above, hypothermia causes characteristic ECG changes because of slowed impulse conduction through potassium channels. This results in prolongation of all the ECG intervals, including RR, PR, QRS, and QT.",
"   </p>",
"   <p>",
"    There may also be elevation of the J point (only if the ST segment is unaltered), producing a characteristic J or Osborn wave that represents distortion of the earliest phase of membrane repolarization (",
"    <a class=\"graphic graphic_waveform graphicRef64520 \" href=\"UTD.htm?41/38/42602\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/30\">",
"     30",
"    </a>",
"    ]. The height of the Osborn wave is roughly proportional to the degree of hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These findings are most prominent in precordial leads V2 to V5; similar findings can be observed in patients with early repolarization, hypercalcemia, and the Brugada syndrome. Shivering can cause a rhythmic irregularity of the ECG baseline, and occasionally the QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef62575 \" href=\"UTD.htm?41/24/42374\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Note that available software for ECG interpretation is unable to recognize Osborn waves, and often misinterprets them as currents of injury (ie, ischemic changes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Airway, breathing, circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of hypothermia requires evaluation and support of the airway, breathing, and circulation; prevention of further heat loss; initiation of rewarming appropriate to the degree of hypothermia; and treatment of complications (",
"    <a class=\"graphic graphic_figure graphicRef73052 \" href=\"UTD.htm?18/12/18638\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/19,33\">",
"     19,33",
"    </a>",
"    ]. A table outlining the emergency management of hypothermia in adults is provided (",
"    <a class=\"graphic graphic_table graphicRef51697 \" href=\"UTD.htm?29/46/30445\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endotracheal intubation is performed in patients with respiratory distress or who cannot protect their airway. Early intubation can facilitate clearance of secretions produced by cold-induced bronchorrhea in patients with altered mental status or a decreased cough reflex. Standard medications can be used to perform rapid sequence intubation;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    is not indicated as a pretreatment agent to reduce bronchorrhea.",
"   </p>",
"   <p>",
"    In the field and in the emergency department, misdiagnosis of a non-perfusing rhythm, even with a cardiac monitor, is a hazard. Peripheral pulses are difficult to palpate in a vasoconstricted bradycardic patient. It is best to check for a central pulse for up to a full minute, using a continuous wave Doppler when available. Alternatively, a focused bedside echocardiogram can be performed.",
"   </p>",
"   <p>",
"    Cardiopulmonary resuscitation (CPR), including chest compressions, should be initiated in patients with accidental hypothermia who sustain a cardiac arrest. Contraindications to chest compressions include: verified DNR (&ldquo;do not resuscitate&rdquo;) status, obviously lethal injuries, a frozen chest wall that is not compressible, and the presence of any signs of life. Always assume some perfusion is occurring when any signs of life are present. We believe that chest compressions",
"    <strong>",
"    </strong>",
"    should be performed in patients who manifest an organized rhythm on a cardiac monitor but have no pulses and no other signs of life.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Patients with moderate or severe hypothermia frequently become disproportionately hypotensive from severe dehydration and fluid shifts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/8,9,14\">",
"     8,9,14",
"    </a>",
"    ]. Two large (14 or 16 gauge) peripheral IVs should be placed. Blood pressure is supported with warmed (40 to 42&ordm;C) crystalloid infusions. Large infusions may be necessary. A central venous catheter may aid with fluid resuscitation and monitoring of central venous pressure and temperature. Temporary placement of a femoral vein catheter is preferred to avoid the precipitation of dysrhythmia from irritation of the right atrium. Low-dose (2 to 5",
"    <span class=\"nowrap\">",
"     microg/min)",
"    </span>",
"    dopamine can be used to maintain blood pressure in cases refractory to volume resuscitation. Other vasopressors are acceptable, but studies to support their use have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. An indwelling bladder catheter is helpful to assess urinary output and fluid shifts.",
"   </p>",
"   <p>",
"    Core temperature should be monitored closely to assess the adequacy of therapy and to prevent iatrogenic hyperthermia. Rough movement and activity must be avoided, as ventricular fibrillation may result [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Duration of resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the neuroprotective effects of hypothermia, complete recovery of patients with hypothermia and cardiac arrest has been well documented despite prolonged resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/38\">",
"     38",
"    </a>",
"    ]. Therefore, under usual circumstances, resuscitative efforts should be continued indefinitely (occasionally for several hours) until the temperature is 32 to 35&ordm;C (90 to 95&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9\">",
"     9",
"    </a>",
"    ]. Resuscitation can be withheld if the body is frozen so completely that chest compressions are impossible or if the nose and mouth are blocked with ice [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rewarming techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rewarming techniques are divided into passive external rewarming, active external rewarming, and active internal core rewarming. The degree of hypothermia determines the techniques implemented: mild hypothermia is treated with passive external rewarming; moderate and refractory mild hypothermia are treated with active external rewarming; and severe (and some cases of refractory moderate) hypothermia is treated with active internal rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Passive external rewarming (PER)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive external rewarming is the treatment of choice for mild hypothermia. It is also used as a supplemental method, when feasible, in patients undergoing aggressive rewarming for moderate to severe hypothermia. After wet clothing is removed, the patient is covered with blankets or other types of insulation. The resulting reduction in heat loss combines with the patient's intrinsic heat production to produce rewarming. Room temperature should be maintained at approximately 24&ordm;C (75&ordm;F).",
"   </p>",
"   <p>",
"    In elderly patients, PER may be unsuccessful in the setting of glycogen depletion, sepsis, or hypovolemia. Many elderly patients lack normal metabolic and cardiovascular homeostasis, and will require active rewarming. The recommended rate of rewarming varies between 0.5 and",
"    <span class=\"nowrap\">",
"     2&ordm;C/hour.",
"    </span>",
"    Strongly consider implementing active rewarming measures if the rate falls below",
"    <span class=\"nowrap\">",
"     0.5&ordm;C/hour",
"    </span>",
"    or if dysrhythmias are present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Passive external rewarming requires physiologic reserve sufficient to generate heat by shivering or by increasing the metabolic rate. Initially, the clinician often will not know if sufficient reserve is present. The elderly, malnourished, and those with severe cardiovascular disease or other major comorbidities are more likely to lack sufficient physiologic reserve.",
"   </p>",
"   <p>",
"    Should the patient fail to respond to passive rewarming, more aggressive measures are implemented. Failure to rewarm should alert the clinician to the possibility of additional causes of hypothermia in addition to environmental exposure (",
"    <a class=\"graphic graphic_table graphicRef58684 \" href=\"UTD.htm?16/46/17133\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Active external rewarming (AER)",
"    </span>",
"    &nbsp;&mdash;&nbsp;During active external rewarming, some combination of warm blankets, heating pads, radiant heat, warm baths, or forced warm air is applied directly to the patient's skin. These methods are indicated for moderate to severe hypothermia (&lt;32&ordm;C) and for patients with mild hypothermia who are unstable, lack physiologic reserve, or fail to respond to passive external rewarming.",
"   </p>",
"   <p>",
"    Individuals should be extracted from the hypothermic environment in the horizontal position when possible. Even low intensity use of peripheral muscles should be avoided, as muscular perfusion and consequently core temperature afterdrop is accelerated by exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/8\">",
"     8",
"    </a>",
"    ]. Especially in chronic hypothermia with dehydration, rewarming of the trunk should be undertaken BEFORE the extremities. These actions are performed in order to minimize hypotension and acidemia due to arterial vasodilation and core temperature afterdrop [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9,14,40\">",
"     9,14,40",
"    </a>",
"    ]. With forced air warming systems, the extremities can be left uncovered initially. This minimizes afterdrop but allows heat transfer.",
"   </p>",
"   <p>",
"    Core temperature afterdrop is a risk of active external rewarming. This complication occurs when the extremities and trunk are warmed simultaneously. Cold, acidemic blood that has pooled in the vasoconstricted extremities of the hypothermic patient returns to the core circulation, causing a drop in temperature and pH. At the same time, removal from the cold environment results in peripheral vasodilation, potentially contributing to precipitous hypotension, inadequate coronary perfusion, and ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/8\">",
"     8",
"    </a>",
"    ]. These phenomena may explain the fatal dysrhythmias that sometimes occur during rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Combining active core rewarming techniques with AER can minimize rewarming shock and afterdrop in patients with severe hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Active internal rewarming (AIR)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Body surface burns are another possible complication of rewarming with heating pads. The combination of decreased sensation and reduced blood flow (which minimizes local heat dissipation) predisposes the hypothermic patient to surface burns. Therefore, the condition of the patient's skin should be frequently assessed during AER. Forced warm air systems are preferable.",
"   </p>",
"   <p>",
"    The core temperature of patients rewarmed using either active external or active internal rewarming techniques generally increases at a rate of at least",
"    <span class=\"nowrap\">",
"     2&ordm;C/hour.",
"    </span>",
"    More hypothermic patients tend to rewarm at a faster rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Active internal rewarming (AIR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active internal rewarming (also called active core rewarming) is the most aggressive strategy. It can be used alone or combined with active external rewarming (AER) in patients with severe hypothermia (&lt; 28&ordm;C) or moderate hypothermia who fail to respond to less aggressive measures. In addition to IV administration of warmed crystalloid (40 to 42&ordm;C), effective techniques include warmed humidified oxygen, irrigation of body cavities with warmed crystalloid, and extracorporeal blood rewarming. Be aware that gastric or colonic irrigation can cause fluid and electrolyte fluctuations, and the surface available for heat exchange in the bladder is minimal.",
"   </p>",
"   <p>",
"    In general, we advocate a stepwise approach beginning with less invasive rewarming techniques. The combination of AIR, using heated IV infusions and warmed humidified oxygen, and AER provides an effective initial strategy for most spontaneously perfusing, severely hypothermic patients. Moreover, there is inadequate evidence to suggest that rapidly increasing the rate of rewarming improves outcomes in this population. If patients fail to respond, irrigation of the peritoneal and pleural cavities with heated crystalloid can be performed. Extracorporeal blood rewarming is performed in extreme cases (eg, cardiac arrest, frozen limb) or when rewarming is inadequate despite the other measures described here. Transferring patients to tertiary care centers is generally unnecessary unless they require extracorporeal rewarming. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Extracorporeal blood rewarming'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although every increment of heat helps, some interventions have limited effect. Airway rewarming with warm humidified oxygen provides only a modest benefit since most humidifiers cannot exceed 41&ordm;C without modification. The ideal setting is 45&ordm;C. Similarly, the amount of heat provided by IV fluid heated to 40 to 42&ordm;C only reaches significance during large volume resuscitations.",
"   </p>",
"   <p>",
"    Peritoneal and pleural irrigation are the AIR techniques most likely to be employed in the emergency department (ED). Peritoneal irrigation can be performed by infusing 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic saline warmed to approximately 42&ordm;C. The fluid is left in the peritoneal cavity for 20 minutes and then removed. The overall exchange rate is 6",
"    <span class=\"nowrap\">",
"     L/hour",
"    </span>",
"    and is most easily accomplished with two catheters, one for instillation and one for drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/14\">",
"     14",
"    </a>",
"    ]. Catheter placement is similar to diagnostic peritoneal lavage.",
"   </p>",
"   <p>",
"    Pleural irrigation can be accomplished by placing two thoracostomy tubes (36 to 40 French) in one or both hemithoraces [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/45\">",
"     45",
"    </a>",
"    ]. One tube is placed high and anterior and the other placed low and posterior in the chest cavity. Warm isotonic saline at a temperature of 40 to 42&ordm;C is infused in 200 to 300 mL amounts through the anterior tube and allowed to drain posteriorly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/46\">",
"     46",
"    </a>",
"    ]. Reserve this technique for the severely hypothermic patient who is not rewarming nor has another indication for a chest tube. Do not insert left-sided tubes in a perfusing patient, since the heart is irritable. Leave the inferior tube for drainage after rewarming.",
"   </p>",
"   <p>",
"    Endovascular warming devices are in development and may serve as an effective and less invasive alternative to cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/47\">",
"     47",
"    </a>",
"    ]. Clinical trials with these devices are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Extracorporeal blood rewarming",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four techniques can be used to directly rewarm blood: venovenous rewarming, hemodialysis, continuous arteriovenous rewarming (CAVR), and cardiopulmonary bypass (CPB) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/15,26,48-55\">",
"     15,26,48-55",
"    </a>",
"    ]. These treatments are reserved for potentially salvageable patients in cardiac arrest, patients who do not rewarm with less invasive active internal rewarming techniques, and those with completely frozen extremities or severe rhabdomyolysis with hyperkalemia. The option selected depends upon clinical circumstance and available resources.",
"   </p>",
"   <p>",
"    A venovenous rewarming circuit requires two IV lines, one of which must be a central venous catheter. A femoral catheter is preferred to avoid the precipitation of dysrhythmia from irritation of the right atrium. Although venovenous rewarming provides no direct oxygenation or circulatory support, flow rates average 150 to 400",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    and rewarming occurs at a rate of 2 to",
"    <span class=\"nowrap\">",
"     3&ordm;C/hour.",
"    </span>",
"    Hemodialysis achieves similar rewarming rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/56\">",
"     56",
"    </a>",
"    ]. CAVR requires a systolic blood pressure of 60 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/49\">",
"     49",
"    </a>",
"    ]. Percutaneous 8.5 French femoral catheters direct blood through a countercurrent heat exchanger, yielding a rewarming rate of 3 to",
"    <span class=\"nowrap\">",
"     4&ordm;C/hour.",
"    </span>",
"   </p>",
"   <p>",
"    CPB can rewarm at rates up to",
"    <span class=\"nowrap\">",
"     9.5&ordm;C/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. One retrospective series documented a 47 percent long-term survival rate with minimal sequelae among 32 patients with severe hypothermia and cardiac arrest treated with CPB [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/52\">",
"     52",
"    </a>",
"    ]. This relatively high survival rate following cardiac arrest likely reflects that many patients in the series were young and previously healthy and asphyxia and anoxic encephalopathy rarely preceded the development of hypothermia. Portable CPB units have also been used to treat hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermic patients may exhibit cardiac irritability. Rough handling runs the risk of precipitating ventricular arrhythmias, including ventricular fibrillation. However, this mostly theoretical concern should not prevent the performance of potentially life-saving interventions.",
"   </p>",
"   <p>",
"    Bradycardia may be physiologic in severe hypothermia, and cardiac pacing generally is",
"    <strong>",
"     not",
"    </strong>",
"    required unless the bradycardia persists despite rewarming to 32 to 35&ordm;C (90 to 95&ordm;F). Atrial fibrillation and flutter do not cause a rapid ventricular response and often resolve spontaneously with rewarming, but the management of ventricular arrhythmias can be problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/9,14,15,53\">",
"     9,14,15,53",
"    </a>",
"    ]. Transcutaneous pacing is less hazardous than transvenous intracardiac pacing for a severe bradycardia that is profoundly disproportionate to temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the lack of evidence regarding management of ventricular arrhythmias in hypothermic patients, it is reasonable to treat patients according to ACLS guidelines, including defibrillation and administration of vasopressors (eg, epinephrine 1 mg IV or vasopressin 40 units IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/59\">",
"     59",
"    </a>",
"    ]. However, ventricular arrhythmias and asystole may be refractory to conventional therapy until the patient has been rewarmed. Thus, the definitive management of arrhythmia is focused on aggressively rewarming the patient in conjunction with standard cardiac life support, including most importantly basic cardiopulmonary resuscitation using excellent technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence to support drug therapy prior to successful rewarming is limited and consists primarily of animal studies. A systematic review of these studies found that vasopressor therapy had a higher association with return of spontaneous circulation than antiarrhythmia medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Failure to rewarm",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who fail to rewarm, the clinician first ensures that appropriately aggressive rewarming techniques are in place. Readily reversible contributing causes, such as hypoglycemia, are addressed. The clinician next investigates other potential causes, including sepsis, adrenal insufficiency, and hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef58684 \" href=\"UTD.htm?16/46/17133\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Rewarming techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hypothermic patients with an obvious source of infection receive antibiotics. In addition, patients who fail to raise their core body temperature greater than",
"    <span class=\"nowrap\">",
"     0.67&ordm;C/hour,",
"    </span>",
"    despite appropriate rewarming efforts, should be treated empirically with broad spectrum intravenous (IV) antibiotics.",
"   </p>",
"   <p>",
"    Rapid rewarming depends in part on the patient's inherent capacity for thermogenesis, which is compromised by underlying infection. This is suggested by a prospective observational study of 88 consecutive hypothermic patients treated at a single major urban emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/21\">",
"     21",
"    </a>",
"    ]. Despite the use of similar rewarming techniques, patients with hypothermia and an underlying infection had slower rewarming rates (below",
"    <span class=\"nowrap\">",
"     0.67&ordm;C/hour)",
"    </span>",
"    compared with patients without infection (above",
"    <span class=\"nowrap\">",
"     1.67&ordm;C/hour).",
"    </span>",
"    Patients with infection accounted for the great majority of deaths, and no patient died from a hypothermia-induced arrhythmia. The authors conclude that among urban patients with hypothermia, infection is a major cause of death that often manifests with slower rewarming rates.",
"   </p>",
"   <p>",
"    Patients who fail to respond to aggressive rewarming measures may also have impaired thermogenesis from noninfectious causes, such as endocrine dysfunction, toxins, and lesions of the central nervous system (",
"    <a class=\"graphic graphic_table graphicRef58684 \" href=\"UTD.htm?16/46/17133\">",
"     table 2",
"    </a>",
"    ). In addition to sepsis, conditions amenable to emergent treatment may include adrenocortical insufficiency and hypothyroidism.",
"   </p>",
"   <p>",
"    Although no evidence exists to guide practice, we believe it is reasonable to treat potential adrenocortical insufficiency with a single dose of glucocorticoid in patients with moderate or severe hypothermia who fail to rewarm at an expected rate despite aggressive rewarming measures. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    4 mg IV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    100 mg IV is reasonable. Dexamethasone may be preferable because it is not measured in serum cortisol assays, if testing to determine adrenal function is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Adrenal crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If history, the patient's medication list, or a surgical scar in the area of the thyroid suggest that hypothyroidism may be contributing to a patient's failure to rewarm, it is reasonable to provide treatment. Severe hypothyroidism (myxedema coma) may be treated empirically with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    250 micrograms IV, after blood is drawn for thyroid function studies. Treatment for adrenal insufficiency is also required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link&amp;anchor=H11#H11\">",
"     \"Myxedema coma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Local injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cold-induced cutaneous injuries is generally supportive. Patients should receive tetanus toxoid and analgesia as indicated. Water bath rewarming (40 to 42&ordm;C) of affected areas for 15 to 30 minutes following stabilization of the core temperature may limit tissue loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15913/abstract/55\">",
"     55",
"    </a>",
"    ]. Frostbite is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=see_link\">",
"       \"Patient information: Hypothermia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A table outlining the emergency management of hypothermia in adults is provided (",
"    <a class=\"graphic graphic_table graphicRef51697 \" href=\"UTD.htm?29/46/30445\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermia is defined as a core temperature below 35&ordm;C (95&ordm;F), and can be further classified by severity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild hypothermia: core temperature 32 to 35&ordm;C (90 to 95&ordm;F); findings include confusion, tachycardia, and increased shivering.",
"     </li>",
"     <li>",
"      Moderate hypothermia: 28 to 32&ordm;C (82 to 90&ordm;F); findings include lethargy, bradycardia and arrhythmia, loss of pupillary reflexes, and decreased shivering.",
"     </li>",
"     <li>",
"      Severe hypothermia: below 28&ordm;C (82&ordm;F); findings include coma, hypotension, arrhythmia, pulmonary edema, and rigidity (",
"      <a class=\"graphic graphic_table graphicRef55728 \" href=\"UTD.htm?22/40/23180\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes and factors contributing to the development of hypothermia include outdoor exposure, cold water submersion, medical conditions (eg, hypothyroidism, sepsis), toxins (eg, ethanol abuse), and medications (eg, oral antihyperglycemics, sedative-hypnotics). Risk increases if the ability to autoregulate core temperature is impaired by medications or underlying disease, as is common among elderly patients (",
"      <a class=\"graphic graphic_table graphicRef58684 \" href=\"UTD.htm?16/46/17133\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper diagnosis and management of hypothermia depend upon the use of a low-reading glass or electronic thermometer to determine core temperature. Many standard thermometers only read down to a minimum of 34&ordm;C (93&ordm;F). An esophageal temperature probe is preferred for severe hypothermia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination and temperature measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation is used to identify potential complications and comorbidities, including lactic acidosis, rhabdomyolysis, bleeding diathesis, and infection. Moderate and severe hypothermia can cause dysrhythmia and prolongation of all electrocardiogram intervals. A list of studies to obtain is included above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory studies and monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Electrocardiographic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management of hypothermia is directed toward resuscitation, assessment of the extent of injury, and rewarming. Endotracheal intubation is performed in patients with respiratory distress or who cannot protect their airway. Patients with moderate or severe hypothermia frequently become hypotensive; aggressive fluid resuscitation is appropriate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Airway, breathing, circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Passive external rewarming is the treatment of choice for mild hypothermia and is a supplemental method in patients with moderate to severe hypothermia. After wet clothing is removed, the patient is covered with blankets or other types of insulation. Room temperature should be maintained at approximately 24&ordm;C (75&ordm;F). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Passive external rewarming (PER)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Active external rewarming is used to treat patients with moderate hypothermia, refractory mild hypothermia, and as an adjunct in severe hypothermia. It consists of some combination of warm blankets, radiant heat, or forced warm air applied directly to the patient's skin. Rewarming of the trunk should be undertaken BEFORE the extremities to minimize hypotension and acidemia due to arterial vasodilation and core temperature afterdrop. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Active external rewarming (AER)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For severe and recalcitrant moderate hypothermia, we suggest initiating treatment with less invasive rewarming techniques (eg, warmed IV crystalloid), and progressively adding more invasive ones (eg, warmed pleural lavage) as needed. Extracorporeal blood rewarming techniques are used to treat perfusing patients who fail to rewarm, have completely frozen extremities, or have severe rhabdomyolysis and hyperkalemia. For salvageable, nonperfusing patients with severe hypothermia, we suggest treatment with cardiopulmonary bypass when that option is readily available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Active internal rewarming (AIR)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rough handling of the moderate or severe hypothermic patient can precipitate arrhythmias, including ventricular fibrillation, that are often unresponsive to defibrillation and medications. Cardiopulmonary resuscitation (CPR) should continue until the patient is rewarmed to 30 to 32&ordm;C (86 to 90&ordm;F), at which point renewed attempts at defibrillation and resuscitation with ACLS medications are undertaken. The neuroprotective effects of low temperature may allow recovery following prolonged arrest. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment of arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail to rewarm appropriately despite aggressive rewarming measures, we suggest treatment with empiric broad spectrum antibiotics and a single dose of glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients may also need treatment for hypoglycemia, myxedema coma, or other contributing causes. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Failure to rewarm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After resuscitation, pay careful attention to potential complications, including hypotension during active rewarming, arrhythmia, hyperkalemia, hypoglycemia, rhabdomyolysis, bladder atony, and bleeding diathesis.",
"     </li>",
"     <li>",
"      Local cold-induced injuries vary in severity independent of the degree of systemic hypothermia. Severe injuries may require prolonged supportive management, escharotomy, or amputation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"       \"Frostbite\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93987682\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/1\">",
"      N&auml;yh&auml; S. Environmental temperature and mortality. Int J Circumpolar Health 2005; 64:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Hypothermia-related deaths--United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2005; 54:173.",
"     </a>",
"    </li>",
"    <li>",
"     Mulcahy AR, Watts MR. Accidental hypothermia: An evidence-based approach. Emergency Medicine Practice EBMedicine.net 2009; 11:1. file://www.cmua.nl/content/SEHLiteratuur/SEH%20literatuurbestanden/Accidental%20Hypothermia%200109.pdf (Accessed on March 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/4\">",
"      Headdon WG, Wilson PM, Dalton HR. The management of accidental hypothermia. BMJ 2009; 338:b2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/5\">",
"      Burke WP. A case report of warm weather accidental hypothermia. J Miss State Med Assoc 2004; 45:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/6\">",
"      MacDonell JE, Wrenn K. Hypothermia in the summer. South Med J 1991; 84:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/7\">",
"      Vassal T, Benoit-Gonin B, Carrat F, et al. Severe accidental hypothermia treated in an ICU: prognosis and outcome. Chest 2001; 120:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/8\">",
"      Giesbrecht GG. Cold stress, near drowning and accidental hypothermia: a review. Aviat Space Environ Med 2000; 71:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/9\">",
"      Jolly BT, Ghezzi KT. Accidental hypothermia. Emerg Med Clin North Am 1992; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/10\">",
"      Hanania NA, Zimmerman JL. Accidental hypothermia. Crit Care Clin 1999; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/11\">",
"      Biem J, Koehncke N, Classen D, Dosman J. Out of the cold: management of hypothermia and frostbite. CMAJ 2003; 168:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/12\">",
"      Lee-Chiong TL Jr, Stitt JT. Disorders of temperature regulation. Compr Ther 1995; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/13\">",
"      Jurkovich GJ. Environmental cold-induced injury. Surg Clin North Am 2007; 87:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/14\">",
"      Danzl DF, Pozos RS. Accidental hypothermia. N Engl J Med 1994; 331:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/15\">",
"      Hector MG. Treatment of accidental hypothermia. Am Fam Physician 1992; 45:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/16\">",
"      Kloos RT. Spontaneous periodic hypothermia. Medicine (Baltimore) 1995; 74:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/17\">",
"      Rescorl D. Environmental emergencies. Crit Care Nurs Clin North Am 1995; 7:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/18\">",
"      Varon J, Sadovnikoff N, Sternbach GL. Hypothermia. Saving patients from the big chill. Postgrad Med 1992; 92:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/19\">",
"      Harchelroad F. Acute thermoregulatory disorders. Clin Geriatr Med 1993; 9:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/20\">",
"      Ranhoff AH. Accidental hypothermia in the elderly. Int J Circumpolar Health 2000; 59:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/21\">",
"      Delaney KA, Vassallo SU, Larkin GL, Goldfrank LR. Rewarming rates in urban patients with hypothermia: prediction of underlying infection. Acad Emerg Med 2006; 13:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/22\">",
"      Ballester JM, Harchelroad FP. Hypothermia: an easy-to-miss, dangerous disorder in winter weather. Geriatrics 1999; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/23\">",
"      Kempainen RR, Brunette DD. The evaluation and management of accidental hypothermia. Respir Care 2004; 49:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/24\">",
"      Mallet ML. Pathophysiology of accidental hypothermia. QJM 2002; 95:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/25\">",
"      Rohrer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. Crit Care Med 1992; 20:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/26\">",
"      Gentilello LM. Advances in the management of hypothermia. Surg Clin North Am 1995; 75:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/27\">",
"      MacLeod DB, Cortinez LI, Keifer JC, et al. The desaturation response time of finger pulse oximeters during mild hypothermia. Anaesthesia 2005; 60:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/28\">",
"      Shapiro BA. Temperature correction of blood gas values. Respir Care Clin N Am 1995; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/29\">",
"      Hansen JE. Arterial blood gases. Clin Chest Med 1989; 10:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/30\">",
"      Nolan J, Soar J. Images in resuscitation: the ECG in hypothermia. Resuscitation 2005; 64:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/31\">",
"      Graham CA, McNaughton GW, Wyatt JP. The electrocardiogram in hypothermia. Wilderness Environ Med 2001; 12:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/32\">",
"      Alsafwah S. Electrocardiographic changes in hypothermia. Heart Lung 2001; 30:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/33\">",
"      Soar J, Perkins GD, Abbas G, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation 2010; 81:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/34\">",
"      Oung CM, English M, Chiu RC, Hinchey EJ. Effects of hypothermia on hemodynamic responses to dopamine and dobutamine. J Trauma 1992; 33:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/35\">",
"      Schr&ouml;der T, Hering JP, Heidelmeyer CF, et al. Dopamine-dependent diastolic dysfunction in moderate hypothermia. J Cardiovasc Pharmacol 1994; 23:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/36\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/37\">",
"      Elenbaas RM, Mattson K, Cole H, et al. Bretylium in hypothermia-induced ventricular fibrillation in dogs. Ann Emerg Med 1984; 13:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/38\">",
"      Gilbert M, Busund R, Skagseth A, et al. Resuscitation from accidental hypothermia of 13.7 degrees C with circulatory arrest. Lancet 2000; 355:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/39\">",
"      Epstein E, Anna K. Accidental hypothermia. BMJ 2006; 332:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/40\">",
"      Harnett RM, O'Brien EM, Sias FR, Pruitt JR. Initial treatment of profound accidental hypothermia. Aviat Space Environ Med 1980; 51:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/41\">",
"      Sterba JA. Efficacy and safety of prehospital rewarming techniques to treat accidental hypothermia. Ann Emerg Med 1991; 20:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/42\">",
"      Golden FS, Hervey GR, Tipton MJ. Circum-rescue collapse: collapse, sometimes fatal, associated with rescue of immersion victims. J R Nav Med Serv 1991; 77:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/43\">",
"      Steele MT, Nelson MJ, Sessler DI, et al. Forced air speeds rewarming in accidental hypothermia. Ann Emerg Med 1996; 27:479.",
"     </a>",
"    </li>",
"    <li>",
"     Delaney KA, Vassallo SU, Goldfrank LR. Thermoregulatory principles. In: Toxicologic Emergencies, 5th, Goldfrank LR, Flomenbaum NE, Lewin NA, et al.  (Eds), Appleton and Lange, Norwalk 1994. p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/45\">",
"      Kjaergaard B, Bach P. Warming of patients with accidental hypothermia using warm water pleural lavage. Resuscitation 2006; 68:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/46\">",
"      Plaisier BR. Thoracic lavage in accidental hypothermia with cardiac arrest--report of a case and review of the literature. Resuscitation 2005; 66:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/47\">",
"      Laniewicz M, Lyn-Kew K, Silbergleit R. Rapid endovascular warming for profound hypothermia. Ann Emerg Med 2008; 51:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/48\">",
"      Hernandez E, Praga M, Alcazar JM, et al. Hemodialysis for treatment of accidental hypothermia. Nephron 1993; 63:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/49\">",
"      Gentilello LM, Cobean RA, Offner PJ, et al. Continuous arteriovenous rewarming: rapid reversal of hypothermia in critically ill patients. J Trauma 1992; 32:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/50\">",
"      Vretenar DF, Urschel JD, Parrott JC, Unruh HW. Cardiopulmonary bypass resuscitation for accidental hypothermia. Ann Thorac Surg 1994; 58:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/51\">",
"      Letsou GV, Kopf GS, Elefteriades JA, et al. Is cardiopulmonary bypass effective for treatment of hypothermic arrest due to drowning or exposure? Arch Surg 1992; 127:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/52\">",
"      Walpoth BH, Walpoth-Aslan BN, Mattle HP, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. N Engl J Med 1997; 337:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/53\">",
"      Mulpur AK, Mirsadraee S, Hassan TB, et al. Refractory ventricular fibrillation in accidental hypothermia: salvage with cardiopulmonary bypass. Perfusion 2004; 19:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/54\">",
"      2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Hypothermia. Circulation 2005; 112(24 Suppl):IV (136).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/55\">",
"      Britt LD, Dascombe WH, Rodriguez A. New horizons in management of hypothermia and frostbite injury. Surg Clin North Am 1991; 71:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/56\">",
"      Caluw&eacute; R, Vanholder R, Dhondt A. Hemodialysis as a treatment of severe accidental hypothermia. Artif Organs 2010; 34:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/57\">",
"      Morita S, Seiji M, Inokuchi S, et al. The efficacy of rewarming with a portable and percutaneous cardiopulmonary bypass system in accidental deep hypothermia patients with hemodynamic instability. J Trauma 2008; 65:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/58\">",
"      Ho JD, Heegaard WG, Brunette DD. Successful transcutaneous pacing in 2 severely hypothermic patients. Ann Emerg Med 2007; 49:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/59\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15913/abstract/60\">",
"      Wira CR, Becker JU, Martin G, Donnino MW. Anti-arrhythmic and vasopressor medications for the treatment of ventricular fibrillation in severe hypothermia: a systematic review of the literature. Resuscitation 2008; 78:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 178 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15913=[""].join("\n");
var outline_f15_34_15913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General findings and progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Geriatric population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination and temperature measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory studies and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electrocardiographic changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Airway, breathing, circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Duration of resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rewarming techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Passive external rewarming (PER)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Active external rewarming (AER)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Active internal rewarming (AIR)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Extracorporeal blood rewarming",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Failure to rewarm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Local injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93987682\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/178|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/12/18638\" title=\"figure 1\">",
"      Management of hypothermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/178|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/46/30445\" title=\"table 1\">",
"      Hypothermia RO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/46/17133\" title=\"table 2\">",
"      Differential dx for hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/40/23180\" title=\"table 3\">",
"      Manifestations of hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/13/29915\" title=\"table 4\">",
"      Lab findings in hypothermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/178|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/38/42602\" title=\"waveform 1\">",
"      Osborn waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/24/42374\" title=\"waveform 2\">",
"      Tremor artifact tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=related_link\">",
"      Drowning (submersion injuries)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=related_link\">",
"      Patient information: Hypothermia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15914="Fungal infections following lung transplantation";
var content_f15_34_15914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fungal infections following lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15914/contributors\">",
"     David W Zaas, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Aimee Zaas, MD, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Scott M Palmer, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/34/15914/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/34/15914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation is an effective treatment for a wide range of advanced lung diseases. While the survival of lung transplant recipients continues to improve, outcomes after lung transplantation remain inferior to other types of solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/1\">",
"     1",
"    </a>",
"    ]. Infectious complications contribute substantially to morbidity and mortality following lung transplantation and account for up to 25 percent of all post-transplant deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal infections are a frequent complication in lung transplant recipients, with attack rates of 11.6 per 1000 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/2\">",
"     2",
"    </a>",
"    ]. Aspergillus and Candida species cause the majority of fungal infections in lung transplant recipients; Cryptococcus spp, the agents of mucormycosis, endemic fungi (Histoplasma, Coccidioides, and Blastomyces spp), Scedosporium spp, Fusarium spp, and dematiaceous molds are other important causes (",
"    <a class=\"graphic graphic_table graphicRef60871 \" href=\"UTD.htm?21/37/22108\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews fungal infections in lung transplant recipients. Bacterial, viral, and mycobacterial infections in lung transplant recipients, as well as the evaluation, treatment, and prophylaxis of infection in solid organ transplant recipients, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients are at high risk of infectious complications due to the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high level of immunosuppression required to prevent rejection.",
"     </li>",
"     <li>",
"      Adverse effects of transplantation on local pulmonary host defenses (loss of lymphatics, reduced mucociliary clearance, decreased cough).",
"     </li>",
"     <li>",
"      Constant environmental contact allowing pathogens direct access into the allograft.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood and type of infection varies with the degree of host immunosuppression, timing since transplantation, nature and duration of antimicrobial prophylaxis, and local hospital and regional microbiology. Pneumonia is the most common type of infection in lung transplant recipients. Bacterial, viral, fungal, and mycobacterial infections all occur at an increased frequency after lung transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of non-Candida fungal infections are acquired through inhalation. Pre-transplant colonization, particularly with filamentous molds (eg, Aspergillus spp), also increases the risk of post-transplant pulmonary fungal infection. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to the direct morbidity and mortality caused by infectious complications, they may also lead to loss of allograft function and contribute to the development of bronchiolitis obliterans syndrome (BOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, in a cohort of 201 lung transplant recipients in which 54 (27 percent) were colonized with Aspergillus spp, such colonization was found to be an independent risk factor for BOS on multivariate analysis (hazard ratio 1.81, 95% CI 1.03-3.19) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMELINE OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidemia usually occurs during the first month following lung transplantation as a result of intensive care unit exposure and recent surgery. Aspergillosis occurs a median of 3.2 months following lung transplantation, with 72 percent of cases occurring within the first six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A general discussion the pattern of infections seen following solid organ transplantation is discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef58770 \" href=\"UTD.htm?21/33/22035\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION FOR INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for infection in lung transplant recipients should follow the general guidelines used in other solid organ transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since pneumonia is the most common type of infection in lung transplant recipients, the diagnostic evaluation of lung transplant patients generally includes early and aggressive evaluation of the lungs as a potential source. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pleural effusions diagnosed within the first three months of transplant also warrant further investigation, particularly in patients with systemic signs of infection. Although often presumed to be benign, some pleural effusions in the early post-transplant period represent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASPERGILLOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus spp are the most common cause of invasive fungal infection following lung transplantation and occur more often among lung transplant recipients compared with recipients of other organs (40.5 versus 1.2 cases per 1000 patient-years among lung transplant recipients and renal transplant recipients, respectively; 4.8 cases per 1000 patient-years among all solid organ transplant recipients) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately 6 percent (range 3 to 15 percent) of lung transplant recipients develop aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A. fumigatus is the most common species implicated in invasive aspergillosis, but other species, such as A. terreus, A. flavus, and A. niger, also cause disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/10\">",
"     10",
"    </a>",
"    ]. A. terreus is of particular importance because it is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Microbial epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients are at increased risk for invasive aspergillosis and other infections compared with other solid organ transplant recipients because of the higher doses of immunosuppression that are required, as well as other factors that are described above. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk of infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Specific risk factors for invasive aspergillosis in lung transplant recipients include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6,9,10,13,14\">",
"     6,9,10,13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway colonization with Aspergillus spp",
"     </li>",
"     <li>",
"      Airway ischemia",
"     </li>",
"     <li>",
"      Bronchiolitis obliterans (rejection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Airway colonization occurs in 25 to 30 percent of lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/9\">",
"     9",
"    </a>",
"    ], but in approximately 50 percent among those with cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/15\">",
"     15",
"    </a>",
"    ]. Cystic fibrosis patients colonized with Aspergillus pre-transplant appear to have an elevated risk of Aspergillus tracheobronchitis, but not of invasive pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recipients of single lung transplants are at risk for aspergillosis in the native lung. In a retrospective study, aspergillosis in single lung transplant recipients was associated with significantly higher mortality than in double lung and heart-lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, single lung transplant recipients were more likely to develop invasive aspergillosis late in the post-transplant course. Those who developed invasive aspergillosis were more likely to have chronic obstructive pulmonary disease, which predisposes to colonization with Aspergillus spp.",
"   </p>",
"   <p>",
"    Risk factors for invasive aspergillosis that are common to all solid organ transplant recipients include rejection, CMV disease, high doses of glucocorticoids, and the use of anti-T cell agents (eg, OKT3, antithymocyte globulin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common manifestations of aspergillosis in lung transplant recipients are tracheobronchitis, pneumonia, and disseminated disease. In a literature review of 78 cases of aspergillosis in lung transplant recipients, tracheobronchitis was responsible for 37 percent of cases, followed by invasive pulmonary aspergillosis (32 percent), bronchial anastomosis infections (20 percent), and disseminated infection (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"     6",
"    </a>",
"    ]. Other sites of involvement may include the sinuses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system (CNS), and less commonly, the vertebrae, intervertebral discs, eyes, pleural space, or skin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tracheobronchial aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchial aspergillosis (TBA) occurs most commonly in lung transplant recipients, typically within three months of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6,9,18,19\">",
"     6,9,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TBA can be asymptomatic and detected only by surveillance bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/20\">",
"     20",
"    </a>",
"    ]. Reported clinical findings have included fever, cough, wheezing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemoptysis.",
"   </p>",
"   <p>",
"    The range of findings in TBA is varied and include simple tracheobronchitis, obstructing bronchial aspergillosis, ulcerative tracheobronchitis, necrotizing pseudomembranous tracheobronchitis, and TBA with bronchopleural fistulae. TBA may also progress to invasive and disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary aspergillosis generally occurs later than tracheobronchial aspergillosis, with median time to diagnosis of six months post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/21\">",
"     21",
"    </a>",
"    ]. Symptoms include fever, dry cough, and dyspnea with or without hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/10\">",
"     10",
"    </a>",
"    ]. Physical exam findings may be consistent with pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the lungs and airways, other common sites of invasive aspergillosis in lung transplant recipients include the sinuses and orbits, and CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/10\">",
"     10",
"    </a>",
"    ]. Rarer manifestations include vertebral osteomyelitis, discitis, endophthalmitis, empyema, retroperitoneal or intraabdominal abscess, pericarditis, and skin lesions. In a literature review that included 78 lung transplant recipients with aspergillosis, disseminated infection occurred in 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the increased risk of pulmonary fungal infections in lung transplant recipients, many centers employ frequent early surveillance bronchoscopies to examine the anastomosis as well as fungal staining and culture of bronchoalveolar lavage (BAL) fluid (",
"    <a class=\"graphic graphic_table graphicRef70685 \" href=\"UTD.htm?28/8/28813\">",
"     table 2",
"    </a>",
"    ). Practices for surveillance bronchoscopy vary widely by transplant center, and in centers that routinely perform bronchoscopy, the primary purpose is to evaluate for allograft rejection and not to survey for infection. In addition, diagnostic bronchoscopies performed based upon clinical need (respiratory symptoms, radiographic abnormalities) are useful for the diagnosis of fungal infection.",
"   </p>",
"   <p>",
"    The diagnosis of tracheobronchial aspergillosis is made by visualization of erythema, pseudomembranes, or ulcerations on bronchoscopy with confirmation by histopathology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal culture (",
"    <a class=\"graphic graphic_picture graphicRef62427 \" href=\"UTD.htm?35/4/35918\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/22\">",
"     22",
"    </a>",
"    ]. Chest computed tomography (CT) can be helpful in patients with tracheobronchial aspergillosis, particularly when there are signs of lung involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although definitive diagnosis of invasive pulmonary aspergillosis requires a biopsy demonstrating tissue invasion, this is not always necessary or practical. More commonly, the diagnosis of pulmonary aspergillosis is made presumptively by chest CT in combination with bronchoscopy with fungal staining and culture. CT scan findings range from consolidation (40 percent) to cavitary lesions (30 percent) to nodular or mass-like lesions (30 percent) (",
"    <a class=\"graphic graphic_picture graphicRef74744 \" href=\"UTD.htm?32/62/33764\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"     6",
"    </a>",
"    ]. The sensitivity of bronchoscopically-obtained culture for the diagnosis of invasive disease ranges from 17 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In cases in which the diagnosis is not established by sampling BAL fluid, obtaining a biopsy for fungal stain and culture as well as histopathology can be helpful.",
"   </p>",
"   <p>",
"    CT or magnetic resonance imaging of the CNS is advised in lung transplant recipients with invasive pulmonary aspergillosis to evaluate for dissemination. Tracheobronchitis, however, would not warrant CNS imaging unless CNS symptoms or signs were present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1838389\">",
"    <span class=\"h3\">",
"     Galactomannan, beta-D-glucan, and PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited regarding the utility of the galactomannan antigenemia assay, the beta-D-glucan assay, or the polymerase chain reaction (PCR) for the diagnosis of invasive aspergillosis in lung transplant recipients. One study evaluated the serum galactomannan assay in 70 lung transplant recipients through prospective monitoring with biweekly monitoring. Using an index cut-off value of &ge;0.66, the assay had a sensitivity of 30 percent, a specificity of 95 percent, with false positives typically occurring in the first week post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/26\">",
"     26",
"    </a>",
"    ]. None of the four patients with tracheobronchial aspergillosis had a positive serum galactomannan assay.",
"   </p>",
"   <p>",
"    Another prospective study evaluated the galactomannan assay in 333 bronchoalveolar lavage samples from 116 lung transplant recipients, two of whom had proven invasive aspergillosis, and four of whom probably had invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/27\">",
"     27",
"    </a>",
"    ]. Using an index cut-off value of &ge;1, the assay had a sensitivity of 60 percent and a specificity of 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study compared the performance of an Aspergillus real-time PCR assay with the galactomannan assay in 150 BAL specimens from lung transplant recipients who underwent bronchoscopy for surveillance or diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/28\">",
"     28",
"    </a>",
"    ]. Of these, 16 patients had proven or probable invasive pulmonary aspergillosis, 26 had Aspergillus colonization, 11 had non-Aspergillus mold colonization, and 97 were negative controls. The sensitivity and specificity of a pan-Aspergillus spp PCR for diagnosing invasive pulmonary aspergillosis were 100 and 88 percent, respectively. In comparison, the sensitivity and specificity of an A. fumigatus-specific PCR were 85 and 96 percent, respectively, and the sensitivity and specificity of the galactomannan assay (using a cut-off value &ge;0.5) were 93 and 89 percent, respectively.",
"   </p>",
"   <p>",
"    Beta-D-glucan is a cell wall component of all fungi. A serum assay for beta-D-glucan is available and can be used to screen for invasive fungal infections, including those caused by Aspergillus spp, Candida spp, Pneumocystis, and other fungi. However, it has not been adequately studied in lung transplant recipients.",
"   </p>",
"   <p>",
"    Although these assays may aid in the diagnosis of aspergillosis, their routine use in lung transplant recipients cannot be recommended until further evidence of benefit is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of invasive aspergillosis involves antifungal therapy, most often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, immunosuppression should be reduced whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tracheobronchial aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of tracheobronchial aspergillosis (TBA) involves systemic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in combination with nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ; in addition, debridement of the bronchial anastomosis is often necessary when a substantial amount of necrotic tissue is present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/23,29\">",
"     23,29",
"    </a>",
"    ]. The use of voriconazole is discussed in the following section. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pulmonary and disseminated aspergillosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bronchoscopic debridement is an important component of therapy for TBA when a substantial amount of necrotic debris is present at the bronchial anastomosis, particularly when there is risk of airway obstruction. When there are ulcerations or bronchitis in the absence of devitalized tissue, there is no role for debridement.",
"   </p>",
"   <p>",
"    Nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    may help treat the devascularized anastomotic site when this is the site of infection, although its therapeutic efficacy has not been proven. Anecdotal reports have described the use of combined systemic and inhaled antifungal agents in the treatment of anastomotic infection resulting in resolution of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/30\">",
"     30",
"    </a>",
"    ]. Occasionally, stenting is required to maintain airway patency.",
"   </p>",
"   <p>",
"    Duration of therapy for TBA has not been adequately studied, and is based on the extent and invasiveness of the infection, the host immune status, and the response to therapy. In uncomplicated cases, several months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    are typically given. Complicated cases necessitate longer therapy, with consideration of lifelong suppressive therapy particularly when the bronchial anastomosis is involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pulmonary and disseminated aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has become the treatment of choice for invasive aspergillosis, including tracheobronchial aspergillosis, and was recommended for this indication by the 2008 Infectious Diseases Society of America guidelines on the treatment of aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/23\">",
"     23",
"    </a>",
"    ]. Recommendations for dosing are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Voriconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    efficacy data come from an international, multicenter randomized open-label trial in which voriconazole was compared with conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    as initial therapy in 277 patients with confirmed or probable acute invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/31\">",
"     31",
"    </a>",
"    ]. Only 5 percent of patients were solid organ transplant recipients; the major underlying conditions were allogeneic hematopoietic cell transplantation, acute leukemia, and other hematologic diseases.",
"   </p>",
"   <p>",
"    The following significant benefits were noted in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    group compared with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    group at 12 weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater likelihood of a complete or partial response (53 versus 32 percent).",
"     </li>",
"     <li>",
"      A lower mortality rate (29 versus 42 percent).",
"     </li>",
"     <li>",
"      A lesser likelihood of the clinician changing the patient to another antifungal agent because of intolerance or poor response (36 versus 80 percent).",
"     </li>",
"     <li>",
"      A lower rate of severe adverse reactions, although 45 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      reported transient visual disturbances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate in patients with invasive aspergillosis.",
"   </p>",
"   <p>",
"    <strong>",
"     An important consideration when giving",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    <strong>",
"     (or other azoles) to solid organ transplant recipients is its significant interactions with",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    <strong>",
"     ,",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    <strong>",
"     , and",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    <strong>",
"     , which lead to increased levels of these immunosuppressants. Thus, dose reduction and careful monitoring of serum concentrations of the immunosuppressant agent is necessary.",
"    </strong>",
"    We also suggest checking a voriconazole trough concentration one week into therapy in all patient receiving treatment for invasive aspergillosis; the goal concentration is &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and &lt;5.5",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"     \"Pharmacology of azoles\", section on 'Voriconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate and lipid formulations of amphotericin B. The echinocandins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ), have some in vitro activity against Aspergillus but have not been studied as first-line therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    , an advanced-generation triazole, may represent an option for patients intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . Posaconazole does not offer specific therapeutic advantages over voriconazole for the treatment of aspergillosis, but does not have side effects of vision changes or photosensitivity that can occur with voriconazole use. However, it has not been studied in randomized trials as a first-line agent for the treatment of invasive aspergillosis. Posaconazole is only available as an oral suspension and should be taken with a fatty meal or liquid nutritional supplement to be effectively absorbed. Gastric acidity is necessary for absorption, so drugs that increase gastric pH (eg, proton pump inhibitors) should be avoided in patients receiving posaconazole. Monitoring of serum trough concentrations should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of azoles\", section on 'Posaconazole'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H33#H33\">",
"     \"Pharmacology of azoles\", section on 'Major drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H30#H30\">",
"     \"Pharmacology of azoles\", section on 'Posaconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination systemic therapy for invasive aspergillosis in solid organ transplantation has not been evaluated adequately. In an observational study of 40 solid organ transplant recipients with invasive aspergillosis, those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    had a 68 percent 90-day survival, compared to 51 percent in historical controls receiving lipid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/32\">",
"     32",
"    </a>",
"    ]. It is not possible to know whether caspofungin provided a benefit since there was no control group that received voriconazole monotherapy.",
"   </p>",
"   <p>",
"    The treatment of invasive aspergillosis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall mortality of invasive aspergillosis is 52 to 55 percent in lung transplant recipients, but varies depending upon the site of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/6,20\">",
"     6,20",
"    </a>",
"    ]. The mortality is approximately 25 percent in those with tracheobronchitis compared with 67 to 82 percent in those with invasive pulmonary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER FUNGAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to Aspergillus spp, other important causes of invasive fungal infection in lung transplant recipients include Candida spp, Cryptococcus spp, endemic fungi, and the agents of mucormycosis. Rarer causes are Fusarium spp, Scedosporium spp, and dematiaceous molds (",
"    <a class=\"graphic graphic_table graphicRef60871 \" href=\"UTD.htm?21/37/22108\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidiasis usually manifests as candidemia during the first month following transplantation, as a result of intensive care unit exposure and recent surgery. In addition to candidemia, disseminated disease and local anastomotic site infections may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. In a survey of bloodstream infections following lung transplantation, Candida was the second most common isolate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/33\">",
"     33",
"    </a>",
"    ]. Despite frequent oropharyngeal colonization and isolation from sputum or bronchoalveolar lavage specimens, invasive pulmonary disease caused by Candida species is exceedingly rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=see_link\">",
"     \"Candida infections of the abdomen and thorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cryptococcosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both pulmonary and disseminated cryptococcal infection may occur in lung transplant recipients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66104 \" href=\"UTD.htm?10/18/10533\">",
"     image 1",
"    </a>",
"    ). The mean incidence of cryptococcal infection is 2 percent among lung transplant recipients compared with 2.8 percent among all solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune reconstitution syndrome (IRIS) following initiation of treatment of cryptococcal disease in solid organ transplant recipients has been reported and should be considered as a potential complication of cryptococcosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/35\">",
"     35",
"    </a>",
"    ]. Reduction of immunosuppression may have contributed to the development of IRIS in some cases. Cryptococcal cellulitis has been reported in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\", section on 'Immune reconstitution inflammatory syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucormycosis is an emerging cause of invasive fungal infections in immunocompromised hosts. Presentation in lung transplant recipients typically consists of pulmonary disease, although bronchial anastomosis infection and gastrointestinal disease have also been reported (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71447 \" href=\"UTD.htm?1/43/1713\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/3,37,38\">",
"     3,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucormycosis is characterized by infarction and necrosis of host tissues that results from invasion of the vasculature by hyphae. The pace is usually fast and the outcome in patients with pulmonary mucormycosis is poor, with mortality rates as high as 87 percent. Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H18#H18\">",
"     \"Mucormycosis (zygomycosis)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Endemic fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endemic fungi that cause infection following solid organ transplantation include Histoplasma capsulatum, Coccidioides immitis, and, rarely, Blastomyces dermatitidis. Infections with endemic fungi may occur as a result of reactivation of dormant infection, new acquisition from the environment, or transmission from donors from endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When endemic fungal infection occurs in solid organ transplant recipients, severe pneumonia and disseminated disease are more likely, and the mortality is higher, compared with immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/57/35736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of blastomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pneumocystis jirovecii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 15 percent of patients who undergo solid organ transplantation develop Pneumocystis jirovecii (formerly P. carinii) pneumonia (PCP) in the absence of prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. The rates are highest among lung and heart-lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/40,41,44,45\">",
"     40,41,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The period of highest risk for PCP following solid organ transplantation is from one to six months following transplantation when prophylaxis is not given. The incidence of PCP has decreased dramatically due to nearly universal prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Invasive fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis against the development of invasive fungal infections in lung transplant recipients is a common, but not universal, practice. When used, prophylaxis is focused on reducing the risk of pulmonary mold infections, such as invasive aspergillosis. Several approaches appear effective in the lung transplant population, including the use of an inhaled antifungal medication or treatment with a systemic azole that has activity against Aspergillus. With regards to inhaled therapy, nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    products, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (ABLC),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , or amphotericin B deoxycholate can be used. We prefer ABLC to amphotericin B deoxycholate since the former agent appears to be associated with a lower rate of adverse effects, and also has a longer half-life and improved lung deposition. (See",
"    <a class=\"local\" href=\"#H91310480\">",
"     'Approach to prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Advantages of inhaled therapy include minimal systemic side effects, and coverage against a broad range of fungal pathogens within the lung. However, at least one center that practices this approach in the early postoperative period reported a relatively high incidence of fungal pleural space infections, suggesting that a disadvantage of inhaled therapy is the failure to prevent systemic fungal infections, including pleural space infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach involves using systemic therapy with an azole with activity against molds, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    . This approach offers the advantage of systemic coverage, but has considerable drug-drug interactions with immunosuppressive medications, as well as potential toxicities, including hepatic dysfunction. (See",
"    <a class=\"local\" href=\"#H91310480\">",
"     'Approach to prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of azoles\", section on 'Hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of prospective comparative studies, it is impossible to determine if there is a single best approach to prevent fungal infection after lung transplantation. Because of the high degree of immunosuppression and seriousness of invasive fungal infection in lung transplant recipients, we believe that some form of antifungal prophylaxis is reasonable in the early postoperative period in all lung transplant recipients.",
"   </p>",
"   <p>",
"    Consistent with this idea, a survey of antifungal prophylaxis practice was conducted in lung transplant centers worldwide in 2009 and 2010; 45 percent of respondents were from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/46\">",
"     46",
"    </a>",
"    ]. Within the first six months following transplantation, 59 percent of centers used universal antifungal prophylaxis. The majority of respondents that used prophylaxis (68 percent) used monotherapy, most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Among the centers that used a combination regimen, most used voriconazole plus nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . The optimal prophylaxis and duration of therapy remains uncertain and should be developed based on center-specific rates of fungal infection and other clinical practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91310480\">",
"    <span class=\"h3\">",
"     Approach to prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated above, the approach to antifungal prophylaxis varies by transplant center. For most patients, we use inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (ABLC) 50 mg daily in extubated patients and 100 mg daily in intubated patients for four days post-transplant and then weekly until hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate use is associated with the side effects of nausea, vomiting, and taste alterations; these side effects occur less frequently with nebulized ABLC (as compared with nebulized amphotericin B deoxycholate in previous studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/48\">",
"     48",
"    </a>",
"    ]. ABLC also has the benefits of having a longer half-life and improved lung deposition compared with amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The use of nebulized amphotericin B formulations has been associated with a low rate of pulmonary fungal infections in the early postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/47\">",
"     47",
"    </a>",
"    ]. However, it should be noted that no randomized trials have been performed that have been powered to compare the efficacy of nebulized administration of the different formulations of amphotericin B.",
"   </p>",
"   <p>",
"    For patients who are colonized with mold pre- or post-transplant, we give a systemic antifungal agent often beginning at the time the patients is listed for transplantation and continued for up to four months post-transplant. Longer or shorter durations might be appropriate, depending on the clinical context and burden of disease.",
"   </p>",
"   <p>",
"    In addition to patients whose respiratory tract is colonized with mold, several other subgroups of patients have been identified that may be at higher risk for fungal infections after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/51\">",
"     51",
"    </a>",
"    ]. These include recipients of a single lung transplant, patients with early airway ischemia, patients with concurrent cytomegalovirus infection, patients receiving antithymocyte globulin, and patients with acquired hypogammaglobulinemia (IgG &lt;400",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    In such individuals, systemic antifungal prophylaxis is likely warranted. Further study is necessary to better define the benefits of antifungal prophylaxis in these patient groups.",
"   </p>",
"   <p>",
"    The choice of antifungal regimen depends on the pathogen as well as patient-specific factors.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is used most commonly when a systemic antifungal agent is indicated. Voriconazole is given as a loading dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV (or 400 mg orally) every 12 hours for two doses, then 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV (or 200 mg orally) every 12 hours. Patients are transitioned from IV to oral therapy as appropriate.",
"    <strong>",
"     When voriconazole (or another azole) is used, the clinician must be aware of its significant interactions with",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    <strong>",
"     ,",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    <strong>",
"     , and",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    <strong>",
"     , and reduce the dose of the immunosuppressant agent accordingly",
"    </strong>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H34#H34\">",
"     \"Pharmacology of azoles\", section on 'Selected clinical effects'",
"    </a>",
"    ). Chest computed tomography is helpful for excluding invasive fungal infection before stopping antifungal therapy, and documentation of negative fungal cultures on BAL is also useful",
"   </p>",
"   <p>",
"    In addition to nebulized or systemic antifungal prophylaxis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    suspension (5 cc swish and swallow four times daily for six months following transplantation) is often used to reduce gastrointestinal colonization with Candida spp. We use nystatin in patients who are not receiving a systemic antifungal agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91310457\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h4\">",
"     Nebulized amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with systemic antifungal agents, nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    offers the advantage of drug delivery to the site of fungal exposure, limitation of systemic toxicity, and a lower likelihood of development of resistance. A few small studies have suggested that nebulized amphotericin B prevents invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/13,47,52\">",
"     13,47,52",
"    </a>",
"    ]. As an example, an observational study of nebulized amphotericin B deoxycholate administration in 126 lung transplant recipients showed a lower incidence of invasive aspergillosis at 12 months following transplantation compared with historical controls (2 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other small studies have suggested that the lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    are also effective for Aspergillus prophylaxis. In a retrospective review in which 61 lung transplant recipients received inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (ABLC), 50 mg every other day for two weeks, then once weekly for at least 13 weeks post-transplant, invasive fungal infection due to Aspergillus fumigatus occurred in only one patient by six months following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/53\">",
"     53",
"    </a>",
"    ]. In an observational study in which 104 lung transplant recipients received nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , the rate of invasive disease (1.9 percent) was similar to historical controls who received nebulized amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small retrospective study evaluated the use of antifungal prophylaxis in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/55\">",
"     55",
"    </a>",
"    ]. The 65 patients who received universal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    prophylaxis had significantly lower rates of invasive aspergillosis at one year post-transplant than the 30 patients who received targeted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    prophylaxis (with or without inhaled amphotericin) for pre- or post-transplant Aspergillus colonization except A. niger (1.5 versus 23 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is another azole that has activity against Aspergillus spp and other molds. It has not been studied adequately for prophylaxis in lung transplant recipients, although it is used at some transplant centers based on its in vitro activity and experience in other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pneumocystis pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the risk of Pneumocystis jirovecii (formerly P. carinii) pneumonia (PCP) in the allografted lung is high, indefinite prophylaxis is recommended for all recipients.",
"   </p>",
"   <p>",
"    A retrospective study evaluated 25 cases of PCP among 1299 solid organ transplant recipients at a single center between 1987 and 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/56\">",
"     56",
"    </a>",
"    ]. The incidence of PCP was highest among lung transplant recipients compared with other organ recipients (22 versus 4.8 cases per 1000 person-transplant years) and did not decline after the first year following transplantation, in contrast to recipients of other organs. No patients developed PCP while receiving prophylaxis, but the duration of prophylaxis was shorter for the recipients of certain organs than is standard currently (eg, lung transplant recipients received prophylaxis for one year; liver transplant recipients did not routinely receive prophylaxis until five years into the study).",
"   </p>",
"   <p>",
"    The incidence of PCP among solid organ transplant recipients has decreased dramatically due to nearly universal prophylaxis. In a meta-analysis of 12 randomized controlled trials that included 1245 immunocompromised patients without HIV infection who had undergone autologous hematopoietic stem cell or solid organ transplantation or had a hematologic malignancy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) prophylaxis was associated with a 91 percent reduction in the occurrence of PCP (RR 0.09, 95% CI 0.02-0.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/57\">",
"     57",
"    </a>",
"    ]. Mortality due to PCP was also significantly reduced (RR 0.17, 95% CI 0.03-0.94), although all-cause mortality was not. No differences in efficacy were found between once-daily and thrice-weekly administration schedules for TMP-SMX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although PCP prophylaxis is highly effective, some cases have still been reported in the setting of prophylaxis. For example, in a series of 609 bronchoscopies performed (surveillance and clinically indicated) in lung and heart-lung transplant recipients at a single center from 1994 to 2002, 23 samples were positive for P. jirovecii, 15 of which were from patients receiving prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/58\">",
"     58",
"    </a>",
"    ]. Seven of these 15 patients were taking inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , which is less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX). Furthermore, two samples were positive in samples obtained from surveillance bronchoscopies, which could have represented colonization rather than infection.",
"   </p>",
"   <p>",
"    TMP-SMX is recommended for all patients who can tolerate it, given its excellent efficacy and its broad spectrum against a range of organisms in addition to P. jirovecii (eg, Toxoplasma gondii, Listeria spp, Nocardia spp, Streptococcus pneumoniae) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/34/15914/abstract/59\">",
"     59",
"    </a>",
"    ]. The usual dosing of TMP-SMX for lung transplant recipients is one double-strength tablet daily or three times per week, continued indefinitely. Daily dosing is favored in patients at increased risk of toxoplasmosis (donor",
"    <span class=\"nowrap\">",
"     seropositive/recipient",
"    </span>",
"    seronegative). For those who are intolerant of TMP-SMX, desensitization should be attempted when possible. Alternative regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections are a frequent complication in lung transplant recipients, with attack rates of 11.6 per 1000 patient-years. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspergillus and Candida species cause the majority of fungal infections in lung transplant recipients. Cryptococcus spp, the agents of mucormycosis, Scedosporium spp, and endemic fungi (Histoplasma, Blastomyces, and Coccidioides spp) are other important causes (",
"      <a class=\"graphic graphic_table graphicRef60871 \" href=\"UTD.htm?21/37/22108\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung transplant recipients are at high risk for infectious complications due to the high level of immunosuppression required to prevent rejection, the adverse effects of transplantation on local pulmonary host defenses (eg, reduced mucociliary clearance), and constant environmental contact allowing pathogens direct access into the allograft. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumonia is the most common type of infection in lung transplant recipients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common manifestations of aspergillosis in lung transplant recipients are tracheobronchitis, pneumonia, and disseminated disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of tracheobronchial aspergillosis is made by visualization of erythema, pseudomembranes, or ulcerations on bronchoscopy with confirmation by histopathology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fungal culture. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although definitive diagnosis of invasive pulmonary aspergillosis requires a biopsy demonstrating tissue invasion, this is not always necessary or practical. More commonly, the diagnosis of pulmonary aspergillosis is made presumptively by chest computed tomography in combination with bronchoscopy with fungal staining and culture. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment of aspergillosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      as initial therapy in lung transplant recipients with Aspergillus tracheobronchitis or invasive aspergillosis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Voriconazole is given as a loading dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (or 400 mg orally) every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (or 200 mg orally) every 12 hours. When voriconazole (or another azole) is used, the clinician must be aware of its significant interactions with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , and reduce the dose of the immunosuppressant agent accordingly. Alternatives to voriconazole include intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate and lipid formulations of amphotericin B. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prevention of invasive aspergillosis\", section on 'Voriconazole'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to systemic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , we suggest nebulized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in all patients with tracheobronchial aspergillosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Bronchoscopic debridement is an important component of therapy in patients with a substantial amount of necrotic debris at the bronchial anastomosis, particularly when there is risk of airway obstruction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tracheobronchial aspergillosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Antifungal prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylaxis against the development of invasive fungal infections in lung transplant recipients is a common, but not universal, practice. When used, prophylaxis is focused on reducing the risk of pulmonary mold infections, such as Aspergillus spp. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Invasive fungal infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose respiratory tract is not known to be colonized with mold, we suggest a nebulized formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      for prophylaxis against Aspergillus and other invasive fungal infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use 50 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      daily in extubated patients and 100 mg daily in intubated patients for four days post-transplant and then weekly until hospital discharge. (See",
"      <a class=\"local\" href=\"#H91310480\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have respiratory tract colonization with mold (especially Aspergillus spp), we suggest antifungal prophylaxis with an oral azole that has activity against molds, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Voriconazole is given as a loading dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (or 400 mg orally) every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (or 200 mg orally) every 12 hours. When voriconazole (or another azole) is used, the clinician must be aware of its significant interactions with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , and reduce the dose of the immunosuppressant agent accordingly. We typically administer systemic antifungal prophylaxis for up to four months post-transplant. (See",
"      <a class=\"local\" href=\"#H91310480\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients not receiving systemic antifungal prophylaxis, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      suspension (5 cc swish and swallow four times daily) for six months following transplantation to reduce gastrointestinal colonization with Candida spp (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H91310480\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend Pneumocystis jirovecii (formerly P. carinii) pneumonia prophylaxis for all lung transplant recipients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pneumocystis pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients who require PCP prophylaxis, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The usual dosing is one double-strength tablet daily or three times per week, continued indefinitely. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pneumocystis pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/1\">",
"      Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.",
"     </a>",
"    </li>",
"    <li>",
"     Pappas, PG MJ, Hajjeh, RA, and the Transplant Associated Infection Surveillance Network (TRANSNET). Prospective surveillance for invasive fungal infections (IFIs) in hematopoetic stem cell (HSCTs) and solid organ transplant (SOTs) recipients in the United States. 43rd Annual Interscience Conference of Antimicrobial Agents and Chemotherapy Chicago, IL 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/3\">",
"      Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/4\">",
"      Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002; 17:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/5\">",
"      Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/6\">",
"      Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/7\">",
"      Wahidi MM, Willner DA, Snyder LD, et al. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/8\">",
"      Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/9\">",
"      Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/10\">",
"      Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/11\">",
"      Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/12\">",
"      Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41:5525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/13\">",
"      Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/14\">",
"      Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/15\">",
"      Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/16\">",
"      Avery RK. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis 2004; 17:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/17\">",
"      Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/18\">",
"      Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991; 144:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/19\">",
"      Fern&aacute;ndez-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/20\">",
"      Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001; 119:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/21\">",
"      Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/22\">",
"      Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/23\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/24\">",
"      Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/25\">",
"      Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/26\">",
"      Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/27\">",
"      Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/28\">",
"      Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/29\">",
"      Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/30\">",
"      Palmer SM, Perfect JR, Howell DN, et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998; 17:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/31\">",
"      Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/32\">",
"      Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/33\">",
"      Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000; 69:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/34\">",
"      Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/35\">",
"      Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/36\">",
"      Rakvit A, Meyerrose G, Vidal AM, et al. Cellulitis caused by Cryptococcus neoformans in a lung transplant recipient. J Heart Lung Transplant 2005; 24:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/37\">",
"      McGuire FR, Grinnan DC, Robbins M. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J Heart Lung Transplant 2007; 26:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/38\">",
"      Manchikalapati P, Canon CL, Jhala N, Eloubeidi MA. Gastrointestinal zygomycosis complicating heart and lung transplantation in a patient with Eisenmenger's syndrome. Dig Dis Sci 2005; 50:1181.",
"     </a>",
"    </li>",
"    <li>",
"     Kauffman CA. Endemic mycoses after hemopoietic stem cell or solid organ transplantation. In: Transplant Infections, 2nd ed, Bowden RA, Ljungman P, Paya CV (Eds), Lippincott Williams and Wilkins, Philadelphia 2003. p.524.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/40\">",
"      Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002; 34:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/41\">",
"      Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995; 155:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/42\">",
"      Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 1995; 162:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/43\">",
"      Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/44\">",
"      Dummer JS, Montero CG, Griffith BP, et al. Infections in heart-lung transplant recipients. Transplantation 1986; 41:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/45\">",
"      Gryzan S, Paradis IL, Zeevi A, et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival. Am Rev Respir Dis 1988; 137:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/46\">",
"      Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation--a world-wide survey. Am J Transplant 2011; 11:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/47\">",
"      Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/48\">",
"      Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/49\">",
"      Sol&eacute; A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int J Antimicrob Agents 2008; 32 Suppl 2:S161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/50\">",
"      Monforte V, Ussetti P, L&oacute;pez R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/51\">",
"      Singh N, Husain S, AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/52\">",
"      Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/53\">",
"      Borro JM, Sol&eacute; A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/54\">",
"      Monforte V, Ussetti P, Gavald&agrave; J, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/55\">",
"      Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/56\">",
"      Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/57\">",
"      Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/58\">",
"      Lehto JT, Koskinen PK, Anttila VJ, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients. Transpl Int 2005; 18:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/34/15914/abstract/59\">",
"      Martin SI, Fishman JA, AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1394 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15914=[""].join("\n");
var outline_f15_34_15914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMELINE OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION FOR INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASPERGILLOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tracheobronchial aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1838389\">",
"      - Galactomannan, beta-D-glucan, and PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tracheobronchial aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pulmonary and disseminated aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER FUNGAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cryptococcosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Endemic fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pneumocystis jirovecii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Invasive fungal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91310480\">",
"      - Approach to prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91310457\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nebulized amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Azoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pneumocystis pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment of aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Antifungal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1394|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/18/10533\" title=\"diagnostic image 1\">",
"      Disseminated cryptococcosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/43/1713\" title=\"diagnostic image 2\">",
"      Pulmonary mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1394|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/33/22035\" title=\"figure 1\">",
"      Infection timeline SOT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1394|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/4/35918\" title=\"picture 1\">",
"      Asperg tracheobronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/62/33764\" title=\"picture 2\">",
"      Pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1394|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/37/22108\" title=\"table 1\">",
"      Lung transplant pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/8/28813\" title=\"table 2\">",
"      BAL studies in immunocompromised hosts with pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=related_link\">",
"      Candida infections of the abdomen and thorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/57/35736?source=related_link\">",
"      Clinical manifestations and diagnosis of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_34_15915="NCCN followup guide HNC";
var content_f15_34_15915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Comprehensive Cancer Network (NCCN) recommended follow-up for head and neck cancers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Posttreatment year",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physical examination frequency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Every one to three months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Every two to four months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3-5",
"      </td>",
"      <td>",
"       Every four to six months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;5",
"      </td>",
"      <td>",
"       Every six to twelve months",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Frequency of physical examination is the same across head and neck cancer sites: paranasal sinus, salivary gland, lip, oral cavity, oropharynx, larynx, hypopharynx, and nasopharynx.",
"    <br>",
"     Additional screening examinations include: thyroid stimulating hormone (TSH) every 6-12 months, if the neck was irradiated; chest imaging as indicated; speech, hearing, and swallowing evaluation and rehabilitation as indicated; and dental evaluation as indicated.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: National Comprehensive Cancer Network guidelines. Available online at: file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed February 26, 2010).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15915=[""].join("\n");
var outline_f15_34_15915=null;
var title_f15_34_15916="Drugs chemicals affecting smell";
var content_f15_34_15916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and chemicals that impair the sense of smell",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amlodipine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a-interferon",
"       </td>",
"       <td>",
"        Single case report, mechanism unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-sympatholytics (beta-blockers)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cadmium",
"       </td>",
"       <td>",
"        Cell toxicity, zinc displacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"       <td>",
"        Microinfarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytosine arabinoside",
"       </td>",
"       <td>",
"        Mucosal tissue death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diltiazem",
"       </td>",
"       <td>",
"        Impairs sensory transmission by nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enalapril",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felodipine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flusinolide*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lovastatin",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"       <td>",
"        Impairs mucosal cell growth and replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine",
"       </td>",
"       <td>",
"        Impairs sensory transmission by nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silver nitrate (argyrosis)",
"       </td>",
"       <td>",
"        Deposition of silver in tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terbinafine",
"       </td>",
"       <td>",
"        Mucosal tissue death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco products and smoke",
"       </td>",
"       <td>",
"        Altered second messenger systems?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Incidence greater than 3 percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Ackerman, BH, Kasbekar, N, Pharmacotherapy 1997; 17:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15916=[""].join("\n");
var outline_f15_34_15916=null;
var title_f15_34_15917="Doses beta agonist preparations";
var content_f15_34_15917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosages of beta agonists used in the routine treatment of asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug and US trade name(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age range approved in US prescribing information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preparation(s)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Short-acting, inhaled beta-2 agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Albuterol (salbutamol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Proventil-HFA&reg;, Ventolin-HFA&reg;, or Pro-Air&reg; metered dose inhaler",
"       </td>",
"       <td>",
"        &ge;4 years old",
"       </td>",
"       <td>",
"        MDI: 90 mcg/puff",
"       </td>",
"       <td>",
"        2 puffs every 4 to 6 hours as needed",
"       </td>",
"       <td>",
"        2 puffs every 4 to 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Proventil&reg;, Ventolin&reg;, or generic solution for nebulization",
"       </td>",
"       <td>",
"        &ge;2 years old",
"       </td>",
"       <td>",
"        <p>",
"         Nebulizer solutions:",
"        </p>",
"        <p>",
"         0.021 percent (0.63 mg/3 mL)",
"        </p>",
"        <p>",
"         0.042 percent (1.25 mg/3 mL)",
"        </p>",
"        <p>",
"         0.083 percent (2.5 mg/3 mL)",
"        </p>",
"        <p>",
"         0.5 percent (2.5 mg/0.5 mL)",
"        </p>",
"       </td>",
"       <td>",
"        2.5 mg every 4 to 6 hours as needed",
"       </td>",
"       <td>",
"        0.1 to 0.15 mg/kg every 4 to 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Levalbuterol (levosalbutamol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Xopenex-HFA&reg; metered dose inhaler",
"       </td>",
"       <td>",
"        &ge;4 years old",
"       </td>",
"       <td>",
"        45 mcg/puff",
"       </td>",
"       <td>",
"        2 puffs every 4 to 6 hours as needed",
"       </td>",
"       <td>",
"        1 to 2 puffs every 4 to 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Xopenex&reg; solution for nebulization",
"       </td>",
"       <td>",
"        &ge;6 years old",
"       </td>",
"       <td>",
"        <p>",
"         Nebulizer solution:",
"        </p>",
"        <p>",
"         0.31/3 mL",
"        </p>",
"        <p>",
"         0.63/3 mL",
"        </p>",
"        <p>",
"         1.25 mg/3 mL",
"        </p>",
"       </td>",
"       <td>",
"        0.63 to 1.25 mg, 2 to 4 times daily, as needed",
"       </td>",
"       <td>",
"        0.31 mg, 2 to 4 times daily, as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Pirbuterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Maxair Autohaler&reg; metered dose inhaler",
"       </td>",
"       <td>",
"        &ge;12 years old",
"       </td>",
"       <td>",
"        Breath-actuated MDI: 200 mcg/puff",
"       </td>",
"       <td>",
"        2 puffs every 4 to 6 hours as needed",
"       </td>",
"       <td>",
"        2 puffs every 4 to 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Long-acting, beta-2 agonists",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Salmeterol",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Serevent&reg; Diskus dry powder inhaler",
"       </td>",
"       <td>",
"        &gt;4 years old",
"       </td>",
"       <td>",
"        DPI: 50 mcg/inhalation",
"       </td>",
"       <td>",
"        1 inhalation every 12 hours",
"       </td>",
"       <td>",
"        1 inhalation every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Formoterol",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Foradil&reg; Aerolizer dry powder inhaler",
"       </td>",
"       <td>",
"        &ge;5 years old",
"       </td>",
"       <td>",
"        DPI: 12 mcg/inhalation",
"       </td>",
"       <td>",
"        1 inhalation every 12 hours",
"       </td>",
"       <td>",
"        1 inhalation every 12 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Weight based pediatric dose should not exceed the usual adult dose shown.",
"    <div class=\"footnotes\">",
"     HFA: hydrofluoroalkane; MDI: metered-dose inhaler; DPI: dry-powder inhaler.",
"     <br/>",
"     * Product strengths shown are according to United States (US) official prescribing information. For non US products, consult local prescribing information for product detail.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     These medications are NEVER used for monotherapy in asthma.",
"     <br/>",
"     &Delta; Salmeterol is also available in combination with fluticasone (Advair&reg;).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Formoterol is also available in combination with budesonide (Symbicort&reg;) or mometasone (Dulera&reg;).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15917=[""].join("\n");
var outline_f15_34_15917=null;
var title_f15_34_15918="RR stroke lisin vs chlor ALLHAT";
var content_f15_34_15918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stroke with lisinopril versus chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of stroke with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of stroke in all studied patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of stroke in total and in some specific subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15918=[""].join("\n");
var outline_f15_34_15918=null;
var title_f15_34_15919="Thymoma CT II";
var content_f15_34_15919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thymoma originating from the left lobe of the thymus. There is a large rounded inhomogeneous retrosternal mass located to the left of the midline (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_34_15919=[""].join("\n");
var outline_f15_34_15919=null;
